[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 15114
1. Williams HC, Wojnarowska F, Kirtschig G, Mason J, Godec TR, Schmidt E, Chalmers JR, Childs M, Walton S, Harman K, Chapman A, Whitham D, Nunn AJ, UK Dermatology Clinical Trials Network BLISTER Study Group: Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet; 2017 Apr 22;389(10079):1630-1638
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Bullous pemphigoid is a blistering skin disorder with increased mortality.
  • We tested whether a strategy of starting treatment with doxycycline gives acceptable short-term blister control while conferring long-term safety advantages over starting treatment with oral corticosteroids.
  • The primary safety outcome was the proportion with severe, life-threatening, or fatal (grade 3-5) treatment-related adverse events by 52 weeks.
  • Analysis (modified intention to treat [mITT] for the superiority safety analysis and mITT and per protocol for non-inferiority effectiveness analysis) used a regression model adjusting for baseline disease severity, age, and Karnofsky score, with missing data imputed.
  • FUNDING: NIHR Health Technology Assessment Programme.

  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license. Published by Elsevier Ltd.. All rights reserved.
  • [Cites] Lancet. 2013 Jan 26;381(9863):320-32 [23237497.001]
  • [Cites] Vet Hum Toxicol. 1988 Oct;30(5):431-43 [3055652.001]
  • [Cites] Singapore Med J. 2000 Jul;41(7):327-30 [11026799.001]
  • [Cites] Clin Exp Dermatol. 2013 Apr;38(3):311-3 [23517364.001]
  • [Cites] J Invest Dermatol. 2015 May;135(5):1445-7 [25560279.001]
  • [Cites] Stat Med. 2003 Jan 30;22(2):169-86 [12520555.001]
  • [Cites] Br J Dermatol. 2015 Jul;173(1):17-8 [26174646.001]
  • [Cites] J Am Acad Dermatol. 2014 Dec;71(6):1191-7 [25174542.001]
  • [Cites] Medicine (Baltimore). 1953 Feb;32(1):1-123 [13024494.001]
  • [Cites] JAMA Dermatol. 2013 Jan;149(1):58-62 [23324757.001]
  • [Cites] J Invest Dermatol. 2012 Aug;132(8):1998-2004 [22418872.001]
  • [Cites] Arch Dermatol. 2010 Nov;146(11):1251-4 [21079062.001]
  • [Cites] Health Technol Assess. 2017 Mar;21(10 ):1-90 [28406394.001]
  • [Cites] J Am Acad Dermatol. 2012 Mar;66(3):479-85 [22056920.001]
  • [Cites] Br J Dermatol. 2015 Jul;173(1):227-34 [25683592.001]
  • [Cites] N Engl J Med. 2002 Jan 31;346(5):321-7 [11821508.001]
  • [Cites] Lancet. 1984 Sep 1;2(8401):486-8 [6147549.001]
  • [Cites] Clin Exp Dermatol. 2016 Jul;41(5):506-9 [26940484.001]
  • [Cites] BMJ. 2008 Jul 09;337:a180 [18614511.001]
  • [Cites] J Invest Dermatol. 2009 Jul;129(7):1681-7 [19177141.001]
  • [Cites] Br J Dermatol. 2015 Apr;172(4):867-77 [25827742.001]
  • [Cites] Trials. 2012 Apr 27;13:50 [22540678.001]
  • [Cites] Br J Dermatol. 2012 Dec;167(6):1200-14 [23121204.001]
  • [Cites] Br J Dermatol. 2016 Apr;174(4):919-21 [26556709.001]
  • [Cites] Cochrane Database Syst Rev. 2010 Oct 06;(10):CD002292 [20927731.001]
  • [Cites] J Invest Dermatol. 2011 Mar;131(3):637-43 [20944650.001]
  • [Cites] Br J Dermatol. 1979 Nov;101(5):521-34 [391261.001]
  • [Cites] Arch Dermatol. 1994 Jun;130(6):753-8 [8002646.001]
  • [Cites] Pharmacol Res. 2011 Feb;63(2):130-45 [20937386.001]
  • (PMID = 28279484.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Investigator] Adams J; Akhras V; Anstey A; Barnard C; Bell H; Blackford S; Bröcker E; Carmichael A; Coelho RR; Craig F; Davies K; Ellis R; English J; Gläser R; Groves R; Günthert C; Hampton PJ; Hepburn N; Hügel R; Hussain K; Ingram J; Layton AM; Levell NJ; Lewis V; Malhomme H; Omerod A; Patel G; Rallan R; Ravenscroft J; Santander H; Steinbrink K; Sticherling M; Thomas C; Vatve M; van Beek N; Venning V; Veysey E; Wachsmuth R; Wahie S; Walker B; Walsh M; Wee J; Westmoreland M; Wong G; Ferguson A; Verpetinske I; Duarte-Williamson E; Antony F; Bower C; Gawkrodger D; Taghipour K; Dunnill MGS; Waters A; Bottomley W; Wright A; Sterling J; Azam A; Gibbs S; Luger T; Salvary I; Lovell C; Ilchyshyn A; Gibbon K; Nik M; Charles-Holmes R; Lavery AL
  •  go-up   go-down


2. White MC, Peterschmidt J, Callahan J, Fitzgerald JE, Close KL: Interval follow up of a 4-day pilot program to implement the WHO surgical safety checklist at a Congolese hospital. Global Health; 2017 Jun 29;13(1):42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interval follow up of a 4-day pilot program to implement the WHO surgical safety checklist at a Congolese hospital.
  • BACKGROUND: The World Health Organisation Surgical Safety Checklist (SSC) improves surgical outcomes and the research question is no longer 'does the SSC work?
  • Over half the participants were following the six processes measures always or most of the time: confirmation of patient identity and the surgical procedure (57%), assessment of difficult intubation risk (72%), assessment of the risk of major blood loss (86%), antibiotic prophylaxis given before skin incision (86%), use of a pulse oximeter (86%), and counting sponges and instruments (71%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Patient Saf Surg. 2014 Mar 28;8:16 [24678854.001]
  • [Cites] BMJ Open. 2013 Aug 15;3(8):e003039 [23950205.001]
  • [Cites] Br J Surg. 2016 Jul;103(8):971-88 [27145169.001]
  • [Cites] Ann Surg. 2013 Apr;257(4):633-9 [23207242.001]
  • [Cites] J Am Coll Surg. 2011 May;212(5):873-9 [21398154.001]
  • [Cites] Ann Surg. 2012 Jan;255(1):44-9 [22123159.001]
  • [Cites] Br J Surg. 2014 Feb;101(3):150-8 [24469615.001]
  • [Cites] Ann Surg. 2016 Jan;263(1):58-63 [25775063.001]
  • [Cites] Anaesthesia. 2015 Dec;70(12):1345-55 [26558855.001]
  • [Cites] Jt Comm J Qual Patient Saf. 2012 Jun;38(6):254-60 [22737776.001]
  • [Cites] Am J Surg. 2014 Jul;208(1):65-72 [24524864.001]
  • [Cites] Surg Infect (Larchmt). 2012 Feb;13(1):50-6 [22390354.001]
  • [Cites] BMJ Qual Saf. 2015 Dec;24(12 ):776-86 [26199428.001]
  • [Cites] Ann Surg. 2015 May;261(5):821-8 [24824415.001]
  • [Cites] N Engl J Med. 2009 Jan 29;360(5):491-9 [19144931.001]
  • [Cites] Ann Surg. 2013 Dec;258(6):856-71 [24169160.001]
  • (PMID = 28662709.001).
  • [ISSN] 1744-8603
  • [Journal-full-title] Globalization and health
  • [ISO-abbreviation] Global Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Checklist / Education / Global surgery / Patient safety
  •  go-up   go-down


3. Skowron K, Jakubicz A, Budzyńska A, Kaczmarek A, Grudlewska K, Reśliński A, Gospodarek-Komkowska E: Microbiological purity assessment of cosmetics used by one and several persons and cosmetics after their expiry date. Rocz Panstw Zakl Hig; 2017;68(2):191-197

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microbiological purity assessment of cosmetics used by one and several persons and cosmetics after their expiry date
  • Background: Microbiological purity of cosmetics provides safety of users during their use, prevents physicochemical changes of a preparation, infections and diseases of the skin.
  • Objective: The aim of this study was to assess the level of microbiological contamination of cosmetics used by one person and by several people and cosmetics after their expiry date in relations to standards for marketed cosmetics, ensuring safety of their use.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28646837.001).
  • [ISSN] 0035-7715
  • [Journal-full-title] Roczniki Panstwowego Zakladu Higieny
  • [ISO-abbreviation] Rocz Panstw Zakl Hig
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


Advertisement
4. Bitzer J, Römer T, Lopes da Silva Filho A: The use of cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms - a review. Eur J Contracept Reprod Health Care; 2017 Jun;22(3):172-182
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms - a review.
  • Hyperandrogenic skin symptoms such as hirsutism, acne, seborrhea and alopecia are associated with significant quality of life and psychological impairment.
  • OBJECTIVE: To review the data on the efficacy and safety of CPA 2 mg/EE 35 μg for the treatment of hyperandrogenic skin symptoms in women.
  • Studies show that therapeutic response in women with hirsutism requires a long-term approach and that hyperandrogenic skin symptoms in patients with PCOS are efficiently treated.
  • Safety and tolerability data are summarized by the pharmacovigilance risk assessment committee (PRAC) of the European Medicine's Agency's (EMA).
  • CONCLUSIONS: This review provides a comprehensive overview about the efficacy of CPA 2 mg/EE 35 μg in the treatment of hyperandrogenic skin symptoms, thus allowing both health care professionals and women to balance the risks and benefits of treatment based on evidence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28447864.001).
  • [ISSN] 1473-0782
  • [Journal-full-title] The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • [ISO-abbreviation] Eur J Contracept Reprod Health Care
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Hyperandrogenism / acne / alopecia / cyproterone acetate / ethinylestradiol / hirsutism / polycystic ovary syndrome / seborrhea
  •  go-up   go-down


5. Bhattacharyya A, Jain N, Prasad S, Jain S, Yadav V, Ghosh S, Sengupta S: Evaluation of therapeutic potential of VB-001, a leave-on formulation, for the treatment of moderate adherent dandruff. BMC Dermatol; 2017 May 03;17(1):5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to determine the efficacy and skin safety of VB-001 antidandruff leave-on formulation in comparison with marketed antidandruff ZPTO shampoo in patients with moderate adherent dandruff of the scalp.
  • The efficacy of each product was evaluated by comparing proportion of subjects who have shown reduction in flaking by ASFS (adherent scalp flaking score) and pruritus by IGA (investigator global assessment) score.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 1975 Jun;64(6):401-5 [237965.001]
  • [Cites] J Clin Aesthet Dermatol. 2011 Sep;4(9):22-42 [21938268.001]
  • [Cites] J Investig Dermatol Symp Proc. 2005 Dec;10(3):194-7 [16382662.001]
  • [Cites] J Investig Dermatol Symp Proc. 2005 Dec;10(3):295-7 [16382685.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18730-5 [18000048.001]
  • [Cites] Int J Cosmet Sci. 2006 Oct;28(5):311-8 [18489295.001]
  • [Cites] Br J Dermatol. 1984 Aug;111(2):235-42 [6235835.001]
  • [Cites] Indian J Dermatol. 2010 Apr-Jun;55(2):130-4 [20606879.001]
  • [Cites] Int J Cosmet Sci. 2012 Aug;34(4):298-306 [22515370.001]
  • [Cites] J Cosmet Dermatol. 2010 Sep;9(3):202-10 [20883293.001]
  • [Cites] J Am Acad Dermatol. 2001 Dec;45(6):897-903 [11712036.001]
  • [Cites] Contact Dermatitis. 2002 Jan;46(1):6-12 [11918580.001]
  • [Cites] Mycoses. 2015 Apr;58(4):215-9 [25676074.001]
  • [Cites] Crit Care Med. 1999 Sep;27(9):1781-6 [10507598.001]
  • [Cites] Arch Dermatol Res. 2002 Jul;294(5):221-30 [12115025.001]
  • (PMID = 28468620.001).
  • [ISSN] 1471-5945
  • [Journal-full-title] BMC dermatology
  • [ISO-abbreviation] BMC Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Anti-fungals / Dandruff / Malassezia / Scalp
  •  go-up   go-down


6. Campbell K, Baker B, Tovar A, Economos E, Williams B, McCauley L: The Association Between Skin Rashes and Work Environment, Personal Protective Equipment, and Hygiene Practices Among Female Farmworkers. Workplace Health Saf; 2017 Jul;65(7):313-321

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Association Between Skin Rashes and Work Environment, Personal Protective Equipment, and Hygiene Practices Among Female Farmworkers.
  • The objective of this study was to assess work-related hygiene practices and the frequency and location of skin rashes due to cutaneous contact with crop-associated materials (e.g., pesticides) for female nursery and fernery workers in Central Florida.
  • A cross-sectional, community-based participatory research study of 237 female nursery and fernery workers between the ages of 19 and 43 years with significant cutaneous contact with foliage crops was conducted using a self-report questionnaire and a skin rash chart assessment tool.
  • Further research is needed to better understand the development of skin rashes among farmworkers, to generate effective prevention strategies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28628754.001).
  • [ISSN] 2165-0969
  • [Journal-full-title] Workplace health & safety
  • [ISO-abbreviation] Workplace Health Saf
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; disease prevention / government regulation / occupational hazards / occupational health and safety programs / workforce
  •  go-up   go-down


7. Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Belousova E, Frost MD, Sauter M, Brakemeier S, de Vries PJ, Berkowitz N, Voi M, Peyrard S, Budde K: Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study. PLoS One; 2017;12(8):e0180939
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The key secondary end point was safety.
  • Subependymal giant cell astrocytoma lesion response was achieved in 48% of patients and skin lesion response in 68% of patients.
  • The overall risk/benefit assessment supports the use of everolimus as a viable treatment option for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Neurol. 2013 Oct;49(4):255-65 [24053983.001]
  • [Cites] J Med Genet. 1996 Jun;33(6):480-4 [8782048.001]
  • [Cites] Curr Neuropharmacol. 2012 Dec;10(4):404-15 [23730262.001]
  • [Cites] Neurology. 2013 Feb 5;80(6):574-80 [23325902.001]
  • [Cites] Radiology. 2002 Oct;225(1):78-82 [12354988.001]
  • [Cites] J Urol. 1998 Jul;160(1):141-5 [9628635.001]
  • [Cites] N Engl J Med. 2006 Sep 28;355(13):1345-56 [17005952.001]
  • [Cites] Nephrol Dial Transplant. 2016 Jan;31(1):111-9 [26156073.001]
  • [Cites] Anticancer Drugs. 2015 Apr;26(4):437-42 [25719621.001]
  • [Cites] BJU Int. 2010 Jan;105(1):101-6 [19493268.001]
  • [Cites] Kidney Int. 2006 Nov;70(10):1777-82 [17003820.001]
  • [Cites] BJU Int. 2004 Oct;94(6):853-7 [15476522.001]
  • [Cites] Ann N Y Acad Sci. 1991;615:125-7 [2039137.001]
  • [Cites] Lancet. 2013 Jan 12;381(9861):125-32 [23158522.001]
  • [Cites] N Engl J Med. 2010 Nov 4;363(19):1801-11 [21047224.001]
  • [Cites] Lancet. 2008 Aug 23;372(9639):657-68 [18722871.001]
  • [Cites] AJR Am J Roentgenol. 2015 Aug;205(2):292-301 [26204278.001]
  • [Cites] Am J Physiol Renal Physiol. 2014 Sep 1;307(5):F560-70 [24920756.001]
  • [Cites] Am J Kidney Dis. 2012 Feb;59(2):276-83 [22130643.001]
  • [Cites] N Engl J Med. 2011 Apr 28;364(17):1595-606 [21410393.001]
  • [Cites] Ann Neurol. 2015 Dec;78(6):929-38 [26381530.001]
  • [Cites] Am J Kidney Dis. 2015 Oct;66(4):638-45 [26165440.001]
  • [Cites] J Urol. 2002 Oct;168(4 Pt 1):1315-25 [12352384.001]
  • [Cites] Lancet. 2013 Mar 9;381(9869):817-24 [23312829.001]
  • [Cites] Ann Intern Med. 2006 Aug 15;145(4):247-54 [16908915.001]
  • (PMID = 28792952.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 9HW64Q8G6G / Everolimus
  •  go-up   go-down


8. Kendall R, Lenoir J, Gerrard S, Scheuerle RL, Slater NK, Tuleu C: Using the Slug Mucosal Irritation Assay to Investigate the Tolerability of Tablet Excipients on Human Skin in the Context of the Use of a Nipple Shield Delivery System. Pharm Res; 2017 Feb 13;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Using the Slug Mucosal Irritation Assay to Investigate the Tolerability of Tablet Excipients on Human Skin in the Context of the Use of a Nipple Shield Delivery System.
  • However concerns exist around dermatological nipple tolerability with no pharmaceutical safety assessment guidance to study local tissue tolerance of the nipple and the areola.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28194635.001).
  • [ISSN] 1573-904X
  • [Journal-full-title] Pharmaceutical research
  • [ISO-abbreviation] Pharm. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; nipple shield delivery system / pediatric / skin tolerability / slug mucosal irritation assay / tablet excipients
  •  go-up   go-down


9. Zhang W, Chen L, Chen J, Wang L, Gui X, Ran J, Xu G, Zhao H, Zeng M, Ji J, Qian L, Zhou J, Ouyang H, Zou X: Silk Fibroin Biomaterial Shows Safe and Effective Wound Healing in Animal Models and a Randomized Controlled Clinical Trial. Adv Healthc Mater; 2017 May;6(10)

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here a silk fibroin film is developed and its translational potential is investigated for skin repair by performing comprehensive preclinical and clinical studies to fully evaluate its safety and effectiveness.
  • In vivo rabbit full-thickness skin defect study shows that the silk fibroin film effectively reduces the average wound healing time with better skin regeneration compared with the commercial wound dressings.
  • Subsequent assessment in porcine model confirms its long-term safety and effectiveness for full-thickness skin defects.
  • Therefore, the study provides systematic preclinical and clinical evidence that the silk fibroin film promotes wound healing thereby establishing a foundation towards its application for skin repair and regeneration in the clinic.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
  • (PMID = 28337854.001).
  • [ISSN] 2192-2659
  • [Journal-full-title] Advanced healthcare materials
  • [ISO-abbreviation] Adv Healthc Mater
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; bench to bedside / controlled clinical trial / silk fibroin biomaterial / skin repair and regeneration / wound healing
  •  go-up   go-down


10. Musazzi UM, Franzè S, Minghetti P, Casiraghi A: Emulsion versus nanoemulsion: how much is the formulative shift critical for a cosmetic product? Drug Deliv Transl Res; 2017 May 15;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, nanoemulsions seemed to improve the penetration of active ingredients through the human skin, comparing to conventional emulsion.
  • In this contest, the risk of a higher systemic exposure of consumer to active ingredients, due to the ability of nanoemulsion to enhance permeation, results a critical attribute that should be evaluated for assuring the consumer safety.
  • The aim of this work was the evaluation of how an oil-in-water (O/W) nanoemulsion can influence the in vitro skin permeation profiles of two model active ingredients with different polarity (i.e., caffeine and ethyl ximenynate).
  • Considering such findings, it is worth observing that there is room for reconsidering the risk assessment of nanoemulsion-based cosmetic products.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28508377.001).
  • [ISSN] 2190-3948
  • [Journal-full-title] Drug delivery and translational research
  • [ISO-abbreviation] Drug Deliv Transl Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Caffeine / Cosmetic / Ethyl ximenynate / Nanoemulsion / Risk assessment
  •  go-up   go-down


11. Zapletalova A, Pata V, Janis R, Kejlova K, Stoklasek P: Objective measurements of skin surface roughness after microdermabrasion treatment. Skin Res Technol; 2017 Aug;23(3):346-353

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Objective measurements of skin surface roughness after microdermabrasion treatment.
  • BACKGROUND: The aim of this article is to present a new methodology for assessment of skin topology using a three-dimensional image (3D).
  • METHODS: The measurement of the skin surface roughness is based on 3D scanning of silicone replicas by chromatic aberration length technique in a contactless manner, i.e. by a polychromatic light beam.
  • Analysis of the skin surface reprints was performed using Talymap, Gold version.
  • Results were analysed by fractal geometry, which allows to evaluate changes of the skin surface before and after application of cosmetics and instrumental cosmetological techniques.
  • The methodology was applied for objective assessment of the effects of diamond microdermabrasion on the skin surface roughness.
  • RESULTS: Based on the results of skin surface scanning after the treatment with diamond microdermabrasion it may be concluded that inequalities of the skin surface are reduced immediately after exfoliation.
  • The entire study ultimately suggests that the instrumental method used only leads to improvement of the skin surface immediately after its application.
  • Thermo vision images of the skin surface temperature were obtained during the application of the abrasive method.
  • The experimental results showed that the skin is rather cooled than heated by the treatment.
  • CONCLUSION: This study is focused on the development of a methodology for objective measurement of changes in treated skin relief using 3D scanning.
  • The output may also include also an enlarged model of the skin surface made by 3D printer, which can serve for illustrative communication with the client.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
  • (PMID = 28083897.001).
  • [ISSN] 1600-0846
  • [Journal-full-title] Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)
  • [ISO-abbreviation] Skin Res Technol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; 3D scanning / claim substantiation / microdermabrasion / replication / skin structure / statistics
  •  go-up   go-down


12. Alfonso JH, Bauer A, Bensefa-Colas L, Boman A, Bubas M, Constandt L, Crepy MN, Goncalo M, Macan J, Mahler V, Mijakoski D, Ramada Rodilla JM, Rustemeyer T, Spring P, John SM, Uter W, Wilkinson M, Giménez-Arnau AM: Minimum standards on prevention, diagnosis and treatment of occupational and work-related skin diseases in Europe - position paper of the COST Action StanDerm (TD 1206). J Eur Acad Dermatol Venereol; 2017 Jun;31 Suppl 4:31-43

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimum standards on prevention, diagnosis and treatment of occupational and work-related skin diseases in Europe - position paper of the COST Action StanDerm (TD 1206).
  • BACKGROUND: Skin diseases constitute up to 40% of all notified occupational diseases in most European countries, predominantly comprising contact dermatitis, contact urticaria, and skin cancer.
  • While insufficient prevention of work-related skin diseases (WRSD) is a top-priority problem in Europe, common standards for prevention of these conditions are lacking.
  • OBJECTIVE: To develop common European standards on prevention and management of WRSD and occupational skin diseases (OSD).
  • Workplace exposure assessment of WRSD/OSD requires full labelling of product ingredients on material safety data sheets helping to identify allergens, irritants and skin carcinogens.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 European Academy of Dermatology and Venereology.
  • (PMID = 28656728.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Cao Z, Wang M, Chen Q, Zhang Y, Dong W, Yang T, Yan G, Zhang X, Pi Y, Xi B, Bu Q: Preliminary assessment on exposure of four typical populations to potentially toxic metals by means of skin wipes under the influence of haze pollution. Sci Total Environ; 2017 Sep 21;613-614:886-893

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary assessment on exposure of four typical populations to potentially toxic metals by means of skin wipes under the influence of haze pollution.
  • To investigate the exposure risk of human beings to nine potentially toxic metals (PTMs), namely, Cu, Cr, Zn, As, Cd, Pb, Ni, Mn, and Co, skin wipe samples were collected from four types of populations, namely, children, undergraduates, security guards, and professional drivers, under different haze pollution levels in Xinxiang, China by using Ghost wipes.
  • Generally, PTM contamination in skin wipes collected during a light haze pollution level was generally higher than that during a heavy haze pollution level, but PTM contamination was comparable between the two haze pollution levels for children.
  • Non-carcinogenic exposure risks to As, Cd, and Pb for all populations were higher than those for the other six elements but all of them were within the acceptable safety threshold, indicating no apparent non-carcinogenic risk.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017. Published by Elsevier B.V.
  • (PMID = 28946377.001).
  • [ISSN] 1879-1026
  • [Journal-full-title] The Science of the total environment
  • [ISO-abbreviation] Sci. Total Environ.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Dermal exposure / Dust / Exposure assessment / Haze levels / Potentially toxic metal
  •  go-up   go-down


14. Roberts DW, Aptula A, Api AM: Structure-Potency Relationships for Epoxides in Allergic Contact Dermatitis. Chem Res Toxicol; 2017 Feb 20;30(2):524-531

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epoxides are known or proposed to be involved in skin sensitization in various ways.
  • To date no quantitative mechanistic models (QMMs) are known for skin sensitization potency of this subcategory of S<sub>N</sub>2 electrophiles.
  • The epoxide QMM predicts the potency of a nonepoxide S<sub>N</sub>2 electrophile (predicted EC3, 0.48%; observed EC3, 0.5%), which suggests that it could form the basis for a more general H-polar S<sub>N</sub>2 QMM that could be a valuable tool in skin sensitization risk assessment for this quite extensive and structurally diverse reaction mechanistic domain.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28121139.001).
  • [ISSN] 1520-5010
  • [Journal-full-title] Chemical research in toxicology
  • [ISO-abbreviation] Chem. Res. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Epoxy Compounds
  •  go-up   go-down


15. Derby BM, Codner MA: Evidence-Based Medicine: Face Lift. Plast Reconstr Surg; 2017 Jan;139(1):151e-167e

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 3. Incorporate risk-reduction strategies during preoperative assessment.
  • 6. Incorporate use of valid patient outcomes assessment tools in their practice to facilitate standardized outcomes reporting in the face-lift literature.
  • SUMMARY: Treating the aged face requires an understanding of bone and soft-tissue anatomy, including the analogous lamellar layers of the face and neck, and the techniques designed to restore youthful skin tone and facial contours.
  • [MeSH-minor] Evidence-Based Medicine. Face / anatomy & histology. Facial Nerve / anatomy & histology. Female. Humans. Male. Patient Safety. Postoperative Complications / prevention & control. Preoperative Care

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28027252.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


16. Inglefield C, Rone-McCrate R, Brooks R, Zhu J, Grant S, DeVore DP: A Two-Phase Pilot Study to Evaluate the Safety and Tolerability of an In Situ Polymerizing Collagen. Dermatol Surg; 2017 Sep;43(9):1115-1119
MedlinePlus Health Information. consumer health - Skin Aging.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Two-Phase Pilot Study to Evaluate the Safety and Tolerability of an In Situ Polymerizing Collagen.
  • OBJECTIVE: Conduct a prospective, single-center, dual-phase open-label study in 8 subjects to evaluate the safety, tolerability, and efficacy of the porcine collagen composition.
  • METHODS: In Phase I, potential hypersensitivity of the collagen composition was evaluated after skin testing in the back (men) or forearms of subjects (women).
  • Improvement of the nasolabial fold was observed by the physicians and confirmed by assessment of high-resolution photographs and Global Aesthetic Improvement Scale scores over the 12-week treatment were maintained.
  • [MeSH-major] Collagen / adverse effects. Collagen / therapeutic use. Cosmetic Techniques / adverse effects. Dermal Fillers / adverse effects. Dermal Fillers / therapeutic use. Skin Aging / drug effects

  • MedlinePlus Health Information. consumer health - Piercing and Tattoos.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28562432.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dermal Fillers; 0 / Polymers; 9007-34-5 / Collagen
  •  go-up   go-down


17. Clouet E, Kerdine-Römer S, Ferret PJ: Comparison and validation of an in vitro skin sensitization strategy using a data set of 33 chemical references. Toxicol In Vitro; 2017 May 21;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison and validation of an in vitro skin sensitization strategy using a data set of 33 chemical references.
  • Allergic contact dermatitis (ACD) is an adverse health effect that develops following repeated exposure to skin sensitizing chemicals.
  • Here, we have selected an ITS (Integrated Testing Strategy) for skin sensitization which focuses on three in vitro methods that covered the first three steps of the AOP (DPRA, SENS-IS or h-CLAT).
  • The aim of this study was to compare these three methods due to the WoE approach based on a 2-out-of-3-assessment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2016. Published by Elsevier Ltd.
  • (PMID = 28539215.001).
  • [ISSN] 1879-3177
  • [Journal-full-title] Toxicology in vitro : an international journal published in association with BIBRA
  • [ISO-abbreviation] Toxicol In Vitro
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; AOP / DPRA / ITS / SENS-IS / Skin sensitization / h-CLAT
  •  go-up   go-down


18. Xiong J, Chiu Y, Pradhan RS, Li X, Li X, Carlson DM, Awni W: Assessment of the effect of ethnicity on linifanib tolerability and pharmacokinetics in patients with cancer. J Clin Oncol; 2011 May 20;29(15_suppl):e13082

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of the effect of ethnicity on linifanib tolerability and pharmacokinetics in patients with cancer.
  • The aim of this assessment was to evaluate the impact of ethnicity on linifanib tolerability and pharmacokinetics (PK) in cancer patients.
  • The impact of ethnicity on tolerability was assessed by evaluating significance of ethnicity on the exposure-safety relationship.
  • Logistic regression analysis was conducted to construct the exposure-safety relationship for eight common adverse events (hypertension, asthenia, GI-abdominal disorder, diarrhea, skin toxicity 1, skin toxicity 2, proteinuria and anorexia).
  • RESULTS: The exposure-safety response analysis showed that ethnicity was not a significant factor influencing the exposure-safety response relationship for any of the tested adverse events.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28019935.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. DuBois JC, Jarratt M, Beger BB, Bradshaw M, Powala CV, Shanler SD: A-101, a Proprietary Topical Formulation of High-Concentration Hydrogen Peroxide Solution: A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of the Dose-Response Profile in Subjects With Seborrheic Keratosis of the Face. Dermatol Surg; 2017 Sep 04;
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Seborrheic keratosis (SK) is a common benign skin tumor, yet no topical treatments are approved in the United States.
  • The primary efficacy assessment was the Physician's Lesion Assessment (PLA), a validated 4-ordinal scale.
  • Local skin reactions were predominantly mild and transient.
  • A-101 solution had a favorable safety and tolerability profile at both concentrations.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28902028.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Parekh M, Ramaiah G, Pashilkar P, Ramanujam R, Johnston P, Ilag LL: A pilot single centre, double blind, placebo controlled, randomized, parallel study of Calmagen® dermaceutical cream and lotion for the topical treatment of tinea and onychomycosis. BMC Complement Altern Med; 2017 Sep 18;17(1):464

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The study aimed to establish the fungicidal, efficacy and safety profile of Calmagen® dermaceutical cream and lotion containing AMYCOT® as a topical treatment in patients with severe to very severe presentations of fungal skin (tinea) and nail infections (onychomycosis).
  • Clinical cure was defined as Investigator Global Assessment (IGA) response of 'cleared' or 'excellent'.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cochrane Database Syst Rev. 2014 Aug 04;(8):CD009992 [25090020.001]
  • [Cites] An Bras Dermatol. 2010 Sep-Oct;85(5):657-67 [21152790.001]
  • [Cites] Skinmed. 2005 Sep-Oct;4(5):305-10 [16282753.001]
  • [Cites] J Am Podiatr Med Assoc. 2014 Sep-Oct;104(5):479-85 [25275736.001]
  • [Cites] Indian J Dermatol Venereol Leprol. 2008 May-Jun;74(3):226-9 [18583788.001]
  • [Cites] J Clin Lab Anal. 2016 Mar;30(2):103-7 [25902908.001]
  • [Cites] Mycopathologia. 2008 Nov-Dec;166(5-6):353-67 [18478357.001]
  • [Cites] J Antimicrob Chemother. 1999 Mar;43(3):411-3 [10223599.001]
  • [Cites] Indian J Dermatol. 2013 Nov;58(6):457-60 [24249898.001]
  • [Cites] J Cutan Med Surg. 2015 Sep-Oct;19(5):440-9 [25857439.001]
  • [Cites] Mycoses. 2008 Sep;51 Suppl 4:2-15 [18783559.001]
  • [Cites] J Am Acad Dermatol. 2013 Apr;68(4):600-8 [23177180.001]
  • [Cites] J Drugs Dermatol. 2015 Mar;14 (3):223-33 [25738843.001]
  • [Cites] Skin Therapy Lett. 2002;7 Suppl 1:6-7 [12432424.001]
  • [Cites] Indian J Dermatol Venereol Leprol. 2000 Jul-Aug;66(4):188-92 [20877072.001]
  • [Cites] Bioorg Med Chem. 2012 Oct 1;20(19):5678-98 [22902032.001]
  • [Cites] J Clin Aesthet Dermatol. 2014 Jul;7(7):10-8 [25053979.001]
  • [Cites] J Clin Microbiol. 2003 Oct;41(10):4817-9 [14532230.001]
  • [Cites] Indian J Dermatol. 2008;53(4):174-8 [19882028.001]
  • [Cites] Indian J Pharmacol. 2013 Nov-Dec;45(6):622-4 [24347774.001]
  • [Cites] J Clin Microbiol. 1977 Jan;5(1):34-8 [833268.001]
  • [Cites] An Bras Dermatol. 2014 Mar-Apr;89(2):259-64 [24770502.001]
  • [Cites] Int J Dermatol. 2008 Jun;47(6):584-7 [18477149.001]
  • [Cites] Int J Dermatol. 1998 Jun;37(6):450-3 [9646136.001]
  • [Cites] J Drugs Dermatol. 2014 Jan;13(1):32-8 [24385117.001]
  • [Cites] J Am Acad Dermatol. 2015 Jul;73(1):62-9 [25956661.001]
  • [Cites] Indian J Dermatol. 2015 Mar-Apr;60(2):153-8 [25814703.001]
  • (PMID = 28923039.001).
  • [ISSN] 1472-6882
  • [Journal-full-title] BMC complementary and alternative medicine
  • [ISO-abbreviation] BMC Complement Altern Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; AMYCOT® / Calmagen® / Cyanobacterium-derived anti-fungal / Natural antifungal / Onychomycosis / Superficial dermatophytosis / Tinea
  •  go-up   go-down


21. Politi Y, Levi A, Lapidoth M: Integrated Cooling-Vacuum-Assisted Non-Fractional 1540 nm Erbium:Glass Laser is Effective in Treating Acne Scars. J Drugs Dermatol; 2016 Nov 01;15(11):1359-1363
MedlinePlus Health Information. consumer health - Scars.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mid-infrared laser skin interaction is characterized by its modest absorption in water and nite penetration to the mid-dermis.
  • OBJECTIVES: To evaluate the safety and efficacy of acne scars treatment using an integrated cooling-vacuum-assisted 1540 nm Erbium: Glass Laser.
  • Average improvement was 3.9 and 4.1 points on the quartile scale used for outcome assessment 1 and 3 months following the last session, respectively.

  • MedlinePlus Health Information. consumer health - Acne.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28095548.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Mason JM, Chalmers JR, Godec T, Nunn AJ, Kirtschig G, Wojnarowska F, Childs M, Whitham D, Schmidt E, Harman K, Walton S, Chapman A, Williams HC, UK Dermatology Clinical Trials Network BLISTER Study Group: Doxycycline compared to prednisolone therapy for patients with bullous pemphigoid: cost-effectiveness analysis of the BLISTER trial. Br J Dermatol; 2017 Sep 22;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Bullous pemphigoid (BP) is an autoimmune blistering skin disorder associated with significant morbidity and mortality.
  • Within-trial analysis used bivariate regression of costs and QALYs, with multiple imputation of missing data, informing a probabilistic assessment of incremental treatment cost-effectiveness from a health service perspective RESULTS: In the base case, there was no robust difference in costs or QALYs per patient at 1 year comparing doxycycline-initiated therapy with prednisolone-initiated therapy (net cost: £959, 95% CI -£24 to £1941; net QALYs: -0.024, 95% CI -0.088 to 0.041).
  • CONCLUSIONS: Consistent with the clinical findings of the BLISTER trial, patients with mild or moderate blistering should receive treatment guided by the safety and effectiveness of the drugs and patient preference - neither strategy is clearly a preferred use of NHS resources.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] This article is protected by copyright. All rights reserved.
  • (PMID = 28940316.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


23. Hecht JR, Patnaik A, Malik I, Venook A, Berlin J, Croghan G, Wiens BL, Visonneau S, Jerian S, Meropol NJ: ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): An updated analysis. J Clin Oncol; 2004 Jul 15;22(14_suppl):3511

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: This phase 2 study assessed the efficacy and safety of ABX-EGF monotherapy in pts with mCRC who previously failed therapy with a fluoropyrimidine and irinotecan or oxaliplatin or both.
  • Of 148 pts with evaluations after 8 weeks, 15 (10.1%; 95%CI: 5.8%, 16.2%) had confirmed partial responses (12 cohort A, 3 cohort B) and 54 (36.5%) had stable disease (39 cohort A, 15 cohort B) by investigator assessment.
  • The most frequent adverse event (AE) was skin rash (> 90%) [3.4% grade 3].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016465.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Tolcher AW, Baird RD, Patnaik A, Moreno Garcia V, Papadopoulos KP, Garrett CR, Olmos D, Shannon KA, Zazulina V, Rubin EH, Smith IC, Ryan J, Smith PD, Taylor A, Learoyd M, Lupinacci L, Yan L, De Bono JS: A phase I dose-escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or metastatic solid tumors. J Clin Oncol; 2011 May 20;29(15_suppl):3004

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objectives of this phase I study were to examine the safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary antitumor activity of the novel combination of MK-2206 with selumetinib.
  • In the MK-2206 QOD dosing schedule, dose-limiting Grade 3 macular skin rash was reported in 2/3 evaluable patients at MK-2206 45 mg QOD with selumetinib 75mg BID; the tolerable dose was MK-2206 45 mg QOD with selumetinib 75 mg QD.
  • Preliminary assessment of PK/PD data suggest no apparent drug-drug interactions with the PK profile of each drug administered in this combination.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28022185.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Ratain MJ, Flaherty KT, Stadler WM, O'Dwyer P, Kaye S, Xiong H, Patnaik A, Gore M, Lee RJ, Eisen T: Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT). J Clin Oncol; 2004 Jul 15;22(14_suppl):4501

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Typical drug-related toxicities were hand-foot skin reaction, rash, fatigue, diarrhea, anorexia and hypertension.
  • Of the 112 pts with RCC, 65 pts have reached the initial 12-week assessment (63 evaluable for response).
  • The randomized portion will provide information about BAY's disease-stabilizing effect and long-term safety, in particular in pts with RCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016014.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Friedman PM, Tolkachjov SN, Geddes ER, Tillman KA, Zachary CB: TRASER: An innovative device for the treatment of nasal telangiectasias. Lasers Surg Med; 2017 Aug;49(6):625-631

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the safety and efficacy of a novel configurable device in the treatment of nasal telangiectasias.
  • METHODS: Fifteen subjects aged 42-73 with Fitzpatrick skin types I and II were treated for nasal telangiectasias of various sizes.
  • Efficacy was measured by blinded analysis of pre and post images and self-assessment by the subjects.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 Wiley Periodicals, Inc.
  • [ErratumIn] Lasers Surg Med. 2017 Oct;49(8):787 [28921617.001]
  • (PMID = 28382712.001).
  • [ISSN] 1096-9101
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; TRASER / Total Reflection Amplification of Spontaneous Emission Radiation / pulse dye laser / pyrromethene / telangiectasias / total internal reflection / tunable wavelength / variable pulse duration
  •  go-up   go-down


27. Pandite L, Burris HA, Jones S, Wilding G, Taylor C, Versola MJ, Smith DA, Stead A, Koch KM, Spector NL: A safety, tolerability, and pharmacokinetic (PK) study of GW572016 in patients with solid tumors. J Clin Oncol; 2004 Jul 15;22(14_suppl):3179

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A safety, tolerability, and pharmacokinetic (PK) study of GW572016 in patients with solid tumors.
  • This phase I monotherapy study evaluated safety, tolerability, and PK in patients with advanced solid tumors at once (QD) and twice daily (BID) dosing schedules.
  • RESULTS: 81 pts with various carcinomas were enrolled; 64 pts (39 QD, 25 BID) included in safety and disease assessment; 57 included in PK.
  • There were no clinically significant changes in the other safety evaluations.
  • The majority of AEs were grade 1 or 2 skin and/or GI toxicities, manageable with symptomatic treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014929.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Thotakura N, Kumar P, Wadhwa S, Raza K, Katare P: Dermatokinetics as an Important Tool to Assess the Bioavailability of Drugs by Topical Nanocarriers. Curr Drug Metab; 2017;18(5):404-411

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To estimate the amount of drug delivery to skin, the scientists have now established techniques for separation of skin layers for the determination of drug concentrations.
  • This forms the basis of pharmacokinetics of drug(s) in skin, i.e., dermatokinetics.
  • Assessment of bioavailability helps in determination of safety and efficacy of topical formulations.
  • CONCLUSION: As the methods used for determination of pharmacokinetics of oral and intravenous formulations are not useful for dermatokinetic assessment, various methods like tape stripping, microdialysis and vasoconstrictor assays are being used for dermatokinetic assessment.
  • These methods are not only useful to determine the drug concentrations in skin layers, but can also be used to correlate the toxic effects of xenobiotics.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
  • (PMID = 28266274.001).
  • [ISSN] 1875-5453
  • [Journal-full-title] Current drug metabolism
  • [ISO-abbreviation] Curr. Drug Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Pharmacokinetics / confocal microscopy / follicular drug penetration / micro dialysis / tape stripping / trypsin digestion / vasoconstrictor assay
  •  go-up   go-down


29. Heinemann V, Fischer von Weikersthal L, Vehling-Kaiser U, Stauch M, Hass H, Dietzfelbinger HF, Oruzio DV, Klein S, Zellmann K, Decker T, Schulze M, Abenhardt W, Puchtler G, Kappauf HW, Mittermueller J, Haberl C, Giessen CA, Moosmann N, Stintzing S: Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer (mCRC): AIO KRK-0104 trial. J Clin Oncol; 2011 May 20;29(15_suppl):3589

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer (mCRC): AIO KRK-0104 trial.
  • : 3589 Background: The AIO KRK-0104 randomized phase II trial investigated the efficacy and safety of two capecitabine-based regimens: CAPIRI plus cetuximab (CAPIRI-C) and CAPOX plus cetuximab (CAPOX-C) in the first-line treatment of metastatic colorectal cancer (mCRC).
  • Treatment related skin toxicity was evaluated separately for capecitabine and cetuximab.
  • The present analysis investigates the correlation of capecitabine-attributed skin toxicity (Cape-ST) and parameters of treatment efficacy.
  • RESULTS: Of 185 recruited patients, 149 patients (CAPIRI-C, n=78; CAPOX-C, n=71) received study treatment beyond the first tumor assessment and were evaluable for efficacy.
  • While cetuximab-specific skin toxicity such as acneiform rash, dry skin and others occurred in >90% of patients, Cape-ST, predominantly hand-foot syndrome, was observed in only 33.2% of patients.
  • CONCLUSIONS: This analysis supports the hypothesis that for the evaluated regimens a correlation exists between capecitabine-specific skin toxicity and treatment efficacy regarding DCR, PFS and OS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28020253.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Jaffray D, Mutic S, Fallone B, Raaymakers B: MO-A-WAB-01: MRI-Guided Radiation Therapy. Med Phys; 2013 Jun;40(6Part23):390

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The concept of integrating a magnetic resonance imaging (MRI) scanner with a therapy radiation source, either a therapy linear accelerator (linac) or <sup>60</sup> Co, emerged as a feasible novel approach for MRI-guided radiation therapy (i.e.
  • MRI offers the capability to visualize soft-tissue as well as to perform physiological assessment of healthy and tumor tissues.
  • Multiple interdependent issues need to be resolved in order to achieve the optimal operation of the MRI scanner and the radiation source(s) such as: a) radiofrequency (RF) interference, b) magnetic field coupling, c) perturbation of the dose deposited in tissue due to the presence of an external magnetic field, and d) escalation of patient skin dose.
  • They will also discuss key aspects related to the clinical implementation of their systems such as safety, applications, workflows, quality control, staffing models for supporting the infrastructure, and preliminary data.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2013 American Association of Physicists in Medicine.
  • (PMID = 28518368.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Dosimetry / Linear accelerators / Magnetic fields / Magnetic resonance / Magnetic resonance imaging / Medical imaging / Radiation therapy / Radiation treatment / Radiotherapy sources / Tissues
  •  go-up   go-down


31. Guarneri A, Cioni M, Rongioletti F: High-dose intravenous immunoglobulin therapy for scleromyxoedema: a prospective open-label clinical trial using an objective score of clinical evaluation system. J Eur Acad Dermatol Venereol; 2017 Jul;31(7):1157-1160

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the safety and efficacy of high-dose intravenous immunoglobulin (IVIg) for the management of scleromyxoedema prospectively using an objective score.
  • The patients were followed-up to a minimum of 6 months, and their disease activity and response to treatment were assessed using the Physician's Global Assessment of disease severity (PGA) and a modified objective skin scoring system for patients with scleroderma (modified Rodnan score system for scleromyxoedema or mRSSS).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 European Academy of Dermatology and Venereology.
  • (PMID = 28370513.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


32. Anukunwithaya T, Tantisira MH, Tantisira B, Khemawoot P: Pharmacokinetics of a Standardized Extract of Centella asiatica ECa 233 in Rats. Planta Med; 2017 May;83(8):710-717

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ECa 233, a standardized extract of <i>Centella asiatica</i>, has been found to exhibit various positive neurological effects and to have a good safety profile.
  • The results showed that all animals had a good tolerability for ECa 233, whereas madecassic and asiatic acids were found in negligible amounts after pharmacokinetic assessment.
  • Both triterpenoids were extensively distributed in the brain, stomach, and skin within 1 h and remained there for at least 4 h after dosing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart · New York.
  • (PMID = 27992940.001).
  • [ISSN] 1439-0221
  • [Journal-full-title] Planta medica
  • [ISO-abbreviation] Planta Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / ECa 233 extract; 0 / Plant Extracts; 0 / Triterpenes; 34540-22-2 / madecassoside; PKO39VY215 / asiaticoside
  •  go-up   go-down


33. Hoffman LK, Kircik L: Efficacy and Safety of Desoximetasone 0.25% Spray in Adult Atopic Dermatitis Subjects: Pilot Study. J Drugs Dermatol; 2017 Sep 01;16(9):919-922

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and Safety of Desoximetasone 0.25% Spray in Adult Atopic Dermatitis Subjects: Pilot Study.
  • BACKGROUND: Atopic dermatitis (AD) is a chronic, relapsing, inflammatory skin disorder.
  • STUDY DESIGN: A single-center, open labeled pilot study was conducted to investigate the efficacy and safety of desoximetasone 0.25% spray for pruritus in adult atopic dermatitis patients.
  • RESULTS: Twice daily application of desoximetasone 0.25% spray to affected areas resulted in a significant reduction in all outcomes (IGA, pruritus, VAS assessment of pruritus) within 1 week of initiation of treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28915287.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Wittwehr C, Aladjov H, Ankley G, Byrne HJ, de Knecht J, Heinzle E, Klambauer G, Landesmann B, Luijten M, MacKay C, Maxwell G, Meek ME, Paini A, Perkins E, Sobanski T, Villeneuve D, Waters KM, Whelan M: How Adverse Outcome Pathways Can Aid the Development and Use of Computational Prediction Models for Regulatory Toxicology. Toxicol Sci; 2017 Feb;155(2):326-336

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Efforts are underway to transform regulatory toxicology and chemical safety assessment from a largely empirical science based on direct observation of apical toxicity outcomes in whole organism toxicity tests to a predictive one in which outcomes and risk are inferred from accumulated mechanistic understanding.
  • We argue that the systematic organization of knowledge into AOP frameworks can inform and help direct the design and development of computational prediction models that can further enhance the utility of mechanistic and in silico data for chemical safety assessment.
  • Examples of AOP-informed model development and its application to the assessment of chemicals for skin sensitization and multiple modes of endocrine disruption are provided.
  • The role of problem formulation, not only as a critical phase of risk assessment, but also as guide for both AOP and complementary model development is described.
  • The contents serve as a vision for how AOPs can be leveraged to facilitate development of computational prediction models needed to support the next generation of chemical safety assessment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © The Author 2016. Published by Oxford University Press on behalf of the Society of Toxicology.
  • [Cites] Toxicol Sci. 2013 Mar;132(1):75-86 [23288054.001]
  • [Cites] J Appl Toxicol. 2015 Nov;35(11):1333-47 [25824844.001]
  • [Cites] Environ Toxicol Chem. 2015 Jul;34(7):1623-33 [25943079.001]
  • [Cites] Toxicology. 2012 Jan 27;291(1-3):18-24 [22120538.001]
  • [Cites] Environ Toxicol Chem. 2010 Mar;29(3):730-41 [20821501.001]
  • [Cites] Chem Res Toxicol. 2015 Oct 19;28(10):1875-87 [26360911.001]
  • [Cites] PLoS One. 2013 May 30;8(5):e63308 [23737943.001]
  • [Cites] Environ Health Perspect. 2016 May;124(5):556-62 [26431337.001]
  • [Cites] J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):51-138 [20574894.001]
  • [Cites] Bioinformatics. 2012 May 1;28(9):1193-201 [22423044.001]
  • [Cites] Regul Toxicol Pharmacol. 2014 Aug;69(3):529-45 [24928565.001]
  • [Cites] Toxicol Sci. 2015 Feb;143(2):319-32 [25338925.001]
  • [Cites] Environ Health Perspect. 2013 Sep;121(9):1002-10 [23771518.001]
  • [Cites] Comp Biochem Physiol C Toxicol Pharmacol. 2016 May-Jun;183-184:36-45 [26875912.001]
  • [Cites] Regul Toxicol Pharmacol. 2010 Dec;58(3):369-81 [20801182.001]
  • [Cites] Ann N Y Acad Sci. 2007 Dec;1115:1-22 [17925349.001]
  • [Cites] ALTEX. 2014;31(3):336-40 [24687303.001]
  • [Cites] Toxicol Sci. 2013 Jun;133(2):234-47 [23475784.001]
  • [Cites] Environ Res. 2012 Aug;117:90-9 [22770859.001]
  • [Cites] Environ Toxicol Chem. 2011 Feb;30(2):265-73 [21072840.001]
  • [Cites] BMC Syst Biol. 2011 May 05;5:63 [21545743.001]
  • [Cites] Int J Androl. 2008 Apr;31(2):209-23 [18217984.001]
  • [Cites] Mutat Res. 2009 Mar-Jun;681(2-3):230-40 [19010444.001]
  • [Cites] Toxicol Sci. 2015 Nov;148(1):14-25 [26500288.001]
  • [Cites] Regul Toxicol Pharmacol. 2014 Aug;69(3):371-9 [24813372.001]
  • [Cites] Toxicol In Vitro. 2014 Feb;28(1):8-12 [24184331.001]
  • [Cites] Environ Sci Technol. 2016 May 3;50(9):4579-86 [26759916.001]
  • [Cites] Bioinformatics. 2015 Feb 15;31(4):471-83 [25236459.001]
  • [Cites] Environ Sci Technol. 2015 Jul 21;49(14):8804-14 [26066997.001]
  • [Cites] Toxicol In Vitro. 2015 Feb;29(1):259-70 [25448812.001]
  • [Cites] Regul Toxicol Pharmacol. 2013 Jun;66(1):116-29 [23535119.001]
  • [Cites] Expert Opin Drug Metab Toxicol. 2015 Feb;11(2):259-71 [25440524.001]
  • [Cites] Nat Biotechnol. 2011 Sep 08;29(9):811-5 [21904331.001]
  • [Cites] Front Pharmacol. 2015 May 27;6:107 [26074819.001]
  • [Cites] Ecotoxicol Environ Saf. 2004 Sep;59(1):1-9 [15261716.001]
  • [Cites] Toxicol Sci. 2011 Dec;124(2):432-45 [21964421.001]
  • [Cites] Toxicol Sci. 2011 Feb;119(2):308-18 [20966114.001]
  • [Cites] Regul Toxicol Pharmacol. 2015 Aug;72(3):514-37 [25863193.001]
  • [Cites] Toxicol Sci. 2014 Dec;142(2):312-20 [25466378.001]
  • [Cites] Regul Toxicol Pharmacol. 2015 Apr;71(3):463-77 [25707856.001]
  • [Cites] Environ Health Perspect. 2014 Dec;122(12):1261-70 [25117432.001]
  • [Cites] Environ Res. 2012 Jul;116:74-84 [22575326.001]
  • [Cites] Regul Toxicol Pharmacol. 2012 Aug;63(3):489-504 [22659254.001]
  • [Cites] Nat Biotechnol. 2015 Sep;33(9):933-40 [26258538.001]
  • [Cites] Chem Res Toxicol. 2012 Jul 16;25(7):1287-302 [22519603.001]
  • [Cites] Toxicology. 2015 Jun 5;332:112-23 [25598226.001]
  • [Cites] Environ Mol Mutagen. 2015 Jul;56(6):520-34 [25733247.001]
  • [Cites] Toxicol Sci. 2015 Nov;148(1):137-54 [26272952.001]
  • [Cites] J Appl Toxicol. 2013 Nov;33(11):1353-64 [23670904.001]
  • [Cites] Altern Lab Anim. 2007 Mar;35(1):25-32 [17411348.001]
  • [Cites] PLoS One. 2016 Jan 12;11(1):e0146594 [26756814.001]
  • [Cites] ALTEX. 2013;30(4):473-86 [24173169.001]
  • [Cites] J Appl Toxicol. 2015 Nov;35(11):1318-32 [25820183.001]
  • [Cites] Bioinformatics. 2015 Feb 15;31(4):453-61 [24994890.001]
  • (PMID = 27994170.001).
  • [ISSN] 1096-0929
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / P42 ES016465
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Keywords] NOTNLM ; AOP / Adverse Outcome Pathways / computational prediction model. / quantitative AOP
  •  go-up   go-down


35. de Cuyper C, Lodewick E, Schreiver I, Hesse B, Seim C, Castillo-Michel H, Laux P, Luch A: Are metals involved in tattoo-related hypersensitivity reactions? A case report. Contact Dermatitis; 2017 Aug 09;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Metal implants and a skin biopsy of a reactive tattoo were analysed for elemental contents by inductively coupled plasma mass spectrometry and synchrotron-based X-ray fluorescence (XRF) spectroscopy.
  • RESULTS: Nickel (Ni) and chromium (Cr) as well as high levels of titanium (Ti) and aluminium were detected in both the skin biopsy and the implants.
  • However, patch tests with an extract of the implants and metallic Ti on the tattooed skin evoked flare-up of the symptoms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
  • (PMID = 28795428.001).
  • [ISSN] 1600-0536
  • [Journal-full-title] Contact dermatitis
  • [ISO-abbreviation] Contact Derm.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; aluminium / chromium / contact allergy / hypersensitivity / metal implant / nickel / osteosynthesis / tattoo allergy / titanium / titanium dioxide
  •  go-up   go-down


36. Woodley DT, Cogan J, Hou Y, Lyu C, Marinkovich MP, Keene D, Chen M: Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients. J Clin Invest; 2017 Aug 01;127(8):3028-3038
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A double-blind, placebo-controlled pilot trial assessed safety and efficacy of topical and intradermal gentamicin in 5 RDEB patients with nonsense mutations.
  • The intradermal arm tested daily intradermal injection of gentamicin solution (8 mg) or placebo into 2 intact skin sites for 2 days in 4 of 5 patients.
  • Primary outcomes were induction of type VII collagen and AFs at the test sites and safety assessment.
  • Newly created type VII collagen varied from 20% to 165% of that expressed in normal human skin and persisted for 3 months.
  • Type VII collagen induction did not generate anti-type VII collagen autoantibodies in patients' blood or skin.
  • [MeSH-minor] Administration, Topical. Adult. Alleles. Autoantibodies / chemistry. Child. Codon, Nonsense. Double-Blind Method. Female. Genes, Recessive. Humans. Injections, Intradermal. Keratinocytes / cytology. Male. Patient Safety. Pilot Projects. Skin / drug effects. Treatment Outcome. Wound Healing

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Ther. 2009 Sep;17(9):1605-15 [19568221.001]
  • [Cites] BMC Med. 2007 Mar 29;5:5 [17394637.001]
  • [Cites] J Invest Dermatol. 2003 Nov;121(5):1021-8 [14708601.001]
  • [Cites] J Clin Invest. 1993 Oct;92(4):1831-9 [7691888.001]
  • [Cites] Br J Dermatol. 2015 Sep;173(3):821-3 [25703736.001]
  • [Cites] J Invest Dermatol. 2008 Sep;128(9):2179-89 [18385758.001]
  • [Cites] N Engl J Med. 2010 Aug 12;363(7):629-39 [20818854.001]
  • [Cites] Arch Dermatol Res. 1994;287(1):16-22 [7726631.001]
  • [Cites] Mol Ther. 2014 Oct;22(10):1741-52 [25155989.001]
  • [Cites] Nat Med. 2004 Jul;10(7):693-5 [15195089.001]
  • [Cites] Nat Genet. 2002 Dec;32(4):670-5 [12426566.001]
  • [Cites] J Am Acad Dermatol. 2013 Dec;69(6):898-908.e7 [24075228.001]
  • [Cites] Nat Med. 2002 Oct;8(10):1166-70 [12244305.001]
  • [Cites] N Engl J Med. 1970 Aug 27;283(9):451-6 [4393577.001]
  • [Cites] J Clin Invest. 2007 Mar;117(3):683-92 [17290305.001]
  • [Cites] Am J Respir Crit Care Med. 2000 Mar;161(3 Pt 1):860-5 [10712334.001]
  • [Cites] Clin Pharmacol Ther. 2007 Jan;81(1):99-103 [17186006.001]
  • [Cites] Mol Ther. 2004 Aug;10(2):318-26 [15294178.001]
  • [Cites] Cell Discov. 2015;1:null [26491543.001]
  • [Cites] J Invest Dermatol. 1995 Feb;104(2):231-5 [7530271.001]
  • [Cites] J Invest Dermatol. 2013 Jul;133(7):1910-3 [23321924.001]
  • [Cites] Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19483-8 [24218596.001]
  • [Cites] Ann Neurol. 2010 Jun;67(6):771-80 [20517938.001]
  • [Cites] J Invest Dermatol. 1993 Sep;101(3):252-5 [8370960.001]
  • [Cites] J Am Acad Dermatol. 2009 Feb;60(2):203-11 [19026465.001]
  • [Cites] Ann Neurol. 2001 Jun;49(6):706-11 [11409421.001]
  • [Cites] J Invest Dermatol. 2014 Apr;134(4):1138-40 [24213372.001]
  • [Cites] Mol Ther. 2007 Mar;15(3):628-35 [17245357.001]
  • [Cites] Hum Mutat. 2011 Oct;32(10):1100-7 [21681854.001]
  • [Cites] J Clin Invest. 1999 Aug;104(4):375-81 [10449429.001]
  • [Cites] J Invest Dermatol. 2001 Mar;116(3):483-4 [11231335.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2014;15:371-94 [24773318.001]
  • [Cites] Nat Med. 1997 Nov;3(11):1280-4 [9359706.001]
  • [Cites] J Cell Biol. 1986 Oct;103(4):1577-86 [3771648.001]
  • [Cites] J Invest Dermatol. 2015 Dec;135(12):3060-7 [26203639.001]
  • [Cites] N Engl J Med. 2003 Oct 9;349(15):1433-41 [14534336.001]
  • [Cites] Mol Ther. 2013 Jul;21(7):1335-44 [23670575.001]
  • [Cites] Mol Ther. 2009 Jan;17(1):26-33 [19018253.001]
  • [Cites] J Clin Invest. 2003 Jan;111(2):251-5 [12531881.001]
  • [Cites] N Engl J Med. 1984 Apr 19;310(16):1007-13 [6369131.001]
  • [Cites] Hum Mutat. 2012 Feb;33(2):327-31 [22058051.001]
  • [Cites] JAMA. 2016 Nov 1;316(17 ):1808-1817 [27802546.001]
  • [Cites] Exp Dermatol. 1992 Dec;1(5):221-9 [1365323.001]
  • [Cites] Trends Genet. 2008 Nov;24(11):552-63 [18937996.001]
  • [Cites] Trends Mol Med. 2012 Nov;18(11):679-88 [23083810.001]
  • [Cites] J Invest Dermatol. 1985 May;84(5):374-7 [4039741.001]
  • [Cites] J Clin Invest. 1988 Mar;81(3):683-7 [3278005.001]
  • [Cites] Science. 2005 Mar 18;307(5716):1773-6 [15774758.001]
  • (PMID = 28691931.001).
  • [ISSN] 1558-8238
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / R01 AR055914; United States / NIAMS NIH HHS / AR / RC4 AR060535
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / COL7A1 protein, human; 0 / Codon, Nonsense; 0 / Collagen Type VII; 0 / Gentamicins; 0 / Protein Synthesis Inhibitors
  •  go-up   go-down


37. Abruzzo A, Armenise N, Bigucci F, Cerchiara T, Gösser MB, Samorì C, Galletti P, Tagliavini E, Brown DM, Johnston HJ, Fernandes TF, Luppi B: Surfactants from itaconic acid: Toxicity to HaCaT keratinocytes in vitro, micellar solubilization, and skin permeation enhancement of hydrocortisone. Int J Pharm; 2017 May 30;524(1-2):9-15

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surfactants from itaconic acid: Toxicity to HaCaT keratinocytes in vitro, micellar solubilization, and skin permeation enhancement of hydrocortisone.
  • One of the most widely used approaches for improving drug permeation across the stratum corneum barrier of the skin is the use of chemical penetration enhancers, such as surfactants.
  • Assessment of impacts on HaCaT keratinocyte cell viability was used as indicator of their potential to cause skin irritation 24h post exposure (Alamar Blue assay).
  • The effect of different surfactant concentrations (up to ten times the critical micellar concentration, CMC) on hydrocortisone (HC) solubility and permeation through porcine skin was also evaluated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier B.V. All rights reserved.
  • (PMID = 28356226.001).
  • [ISSN] 1873-3476
  • [Journal-full-title] International journal of pharmaceutics
  • [ISO-abbreviation] Int J Pharm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Cytotoxicity / Hydrocortisone / Keratinocyte / Micellar solubilization / Skin permeation enhancement / Surfactants
  •  go-up   go-down


38. Barbero AM, Frasch HF: Effect of stratum corneum heterogeneity, anisotropy, asymmetry and follicular pathway on transdermal penetration. J Control Release; 2017 Aug 28;260:234-246

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A quantitative and thorough study of skin permeation is essential for chemical exposure assessment and transdermal delivery of drugs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier B.V.
  • (PMID = 28596104.001).
  • [ISSN] 1873-4995
  • [Journal-full-title] Journal of controlled release : official journal of the Controlled Release Society
  • [ISO-abbreviation] J Control Release
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Corneocyte / Diffusion / Lag time / Lipid bilayers / Partition coefficient / Skin appendages
  •  go-up   go-down


39. Fiume MM, Heldreth B, Boyer I, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW, Andersen FA: Safety Assessment of Cross-Linked Alkyl Acrylates as Used in Cosmetics. Int J Toxicol; 2017 Sep/Oct;36(5_suppl2):59S-88S

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety Assessment of Cross-Linked Alkyl Acrylates as Used in Cosmetics.
  • The Cosmetic Ingredient Review (CIR) Expert Panel assessed the safety of cross-linked alkyl acrylates as used in cosmetics.
  • The 23 cross-linked alkyl acrylates included in this safety assessment are reported to function as absorbents, film formers, emulsion stabilizers, viscosity increasing agents, suspending agents, binders, and/or skin-conditioning agents.
  • Because data were not available for the individual ingredients, and because residual monomer may be present, the Panel extrapolated from previous reports to support safety.
  • For those ingredients polymerized in benzene, the data available were insufficient to make a determination of safety.
  • A risk assessment for the amount of benzene present would be needed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 29025328.001).
  • [ISSN] 1092-874X
  • [Journal-full-title] International journal of toxicology
  • [ISO-abbreviation] Int. J. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; cosmetics / cross-linked alkyl amides / safety
  •  go-up   go-down


40. Agarwala SS, Thompson J, Smithers M, Ross M, Coventry B, Minor D, Scoggins C, Hersey P, Wachter E: Chemoablation of melanoma with intralesional rose bengal (PV-10). J Clin Oncol; 2009 May 20;27(15_suppl):9060

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An additional 1-2 lesions, including visceral lesions, remain untreated for assessment of bystander response.
  • A modified Fleming design allows interim assessment of safety and OR at weeks 4 and 24, respectively, after treatment of the 20<sup>th</sup> and 40<sup>th</sup> subjects.
  • RESULTS: Interim safety data for the first 40 subjects treated is comparable to phase 1, with transient mild to moderate locoregional pain, vesicles or edema most common; Grade 3 AEs have been rare (1 case each of vesicles and skin flap necrosis), with no Grade 4 or 5 AEs attributed to PV-10.
  • CONCLUSIONS: The safety and efficacy profile of intralesional therapy with PV-10 compares favorably with available therapeutic options for this patient population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962145.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Liu Y, Flynn TJ: CYP3A4 inhibition by &lt;i&gt;Psoralea corylifolia&lt;/i&gt; and its major components in human recombinant enzyme, differentiated human hepatoma HuH-7 and HepaRG cells. Toxicol Rep; 2015;2:530-534

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • <i>Psoralea corylifolia</i> (<i>P. corylifolia</i>) is a medicinal plant used primarily in herbal dietary supplements to treat skin diseases, such as vitiligo and psoriasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Xenobiotica. 2009 Mar;39(3):205-17 [19280519.001]
  • [Cites] Ann Hepatol. 2009 Jul-Sep;8(3):258-66 [19841509.001]
  • [Cites] Fitoterapia. 2013 Oct;90:44-56 [23831482.001]
  • [Cites] Aliment Pharmacol Ther. 2013 Jan;37(1):3-17 [23121117.001]
  • [Cites] Expert Opin Drug Metab Toxicol. 2012 Jul;8(7):909-20 [22568886.001]
  • [Cites] Clin Toxicol (Phila). 2009 Aug;47(7):683-5 [19640237.001]
  • [Cites] Pharmacogn Rev. 2010 Jan;4(7):69-76 [22228944.001]
  • [Cites] Biochem Pharmacol. 2013 Aug 15;86(4):529-38 [23732297.001]
  • [Cites] Drug Metab Dispos. 2006 Jan;34(1):75-83 [16204462.001]
  • [Cites] Arch Pharm Res. 2010 Feb;33(2):225-30 [20195822.001]
  • [Cites] Toxicol Lett. 2012 Feb 25;209(1):67-77 [22173200.001]
  • [Cites] Drug Metab Dispos. 2009 Dec;37(12):2330-9 [19773538.001]
  • [Cites] Curr Drug Metab. 2013 Nov;14 (9):946-68 [24160292.001]
  • [Cites] Dermatol Clin. 2014 Jul;32(3):399-413, ix-x [24891061.001]
  • [Cites] Toxicol In Vitro. 2009 Jun;23(4):748-53 [19328226.001]
  • [Cites] Pharmacol Ther. 2010 Feb;125(2):230-48 [19951720.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Jul 5;821(1):67-74 [15905140.001]
  • [Cites] Drug Metab Rev. 2007;39(4):699-721 [18058330.001]
  • [Cites] Clin Toxicol (Phila). 2005;43(6):589-91 [16255343.001]
  • (PMID = 28962388.001).
  • [ISSN] 2214-7500
  • [Journal-full-title] Toxicology reports
  • [ISO-abbreviation] Toxicol Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Keywords] NOTNLM ; CYP3A4 inhibition / HepaRG cells / Hepatotoxicity / HuH-7 cells / Human recombinant CYP3A4 / Isopsoralen / Isopsoralen (PubChem CID: 10658) / Psoralea corylifolia / Psoralen / Psoralen (PubChem CID: 6199)
  •  go-up   go-down


42. Chalmers JR, Haines RH, Mitchell EJ, Thomas KS, Brown SJ, Ridd M, Lawton S, Simpson EL, Cork MJ, Sach TH, Bradshaw LE, Montgomery AA, Boyle RJ, Williams HC: Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (The BEEP trial): protocol for a randomised controlled trial. Trials; 2017 Jul 21;18(1):343

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Atopic eczema (AE) is a common skin problem that impairs quality of life and is associated with the development of other atopic diseases including asthma, food allergy and allergic rhinitis.
  • Participating families will be randomised in a 1:1 ratio to receive general infant skin-care advice, or general skin-care advice plus emollients with advice to apply daily to the infant for the first year of life.
  • The primary outcome will be a blinded assessment of AE at 24 months of age using the UK Working Party Diagnostic Criteria for Atopic Eczema.
  • Secondary outcomes are other definitions of AE, time to AE onset, severity of AE (EASI and POEM), presence of other allergic diseases including food allergy, asthma and hay fever, allergic sensitisation, quality of life, cost-effectiveness and safety of the emollients.
  • DISCUSSION: This trial will demonstrate whether skin-barrier enhancement through daily emollient for the first year of life can prevent AE from developing in high-risk infants.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacoeconomics. 2003;21(2):105-13 [12515572.001]
  • [Cites] Br J Dermatol. 2011 Aug;165(2):329-34 [21564067.001]
  • [Cites] Br J Dermatol. 2017 Apr;176(4):979-984 [27858989.001]
  • [Cites] Nat Genet. 2009 May;41(5):602-8 [19349982.001]
  • [Cites] J Allergy Clin Immunol. 2015 Jan;135(1):164-70 [25457149.001]
  • [Cites] Health Econ. 1997 Jul-Aug;6(4):327-40 [9285227.001]
  • [Cites] J Am Acad Dermatol. 2016 Nov;75(5):1038-1044 [27522613.001]
  • [Cites] Health Econ. 2001 Dec;10(8):779-87 [11747057.001]
  • [Cites] J Allergy Clin Immunol. 2014 Oct;134(4):818-23 [25282563.001]
  • [Cites] Arch Dis Child. 2011 Mar;96(3):227-31 [21068081.001]
  • [Cites] Int J Technol Assess Health Care. 2005 Spring;21(2):240-5 [15921065.001]
  • [Cites] Allergy Asthma Immunol Res. 2011 Apr;3(2):67-73 [21461244.001]
  • [Cites] J Allergy Clin Immunol. 2014 Oct;134(4):824-830.e6 [25282564.001]
  • [Cites] Br J Dermatol. 2016 Nov;175(5):1011-1019 [27097823.001]
  • [Cites] J Allergy Clin Immunol. 2016 Apr;137(4):1071-8 [26897122.001]
  • [Cites] Pediatrics. 2004 May;113(5):1195-203 [15121929.001]
  • [Cites] J Allergy Clin Immunol. 2013 Dec;132(6):1337-47 [24035157.001]
  • [Cites] Value Health. 2015 Mar;18(2):161-72 [25773551.001]
  • [Cites] Nat Genet. 2006 Apr;38(4):441-6 [16550169.001]
  • [Cites] Clin Exp Allergy. 2015 Jan;45(1):255-64 [25210971.001]
  • [Cites] J Allergy Clin Immunol. 2012 Dec;130(6):1260-74 [23195525.001]
  • [Cites] Allergy. 2017 Mar;72 (3):453-461 [27670637.001]
  • [Cites] Nat Genet. 2007 May;39(5):650-4 [17417636.001]
  • [Cites] N Engl J Med. 2011 Oct 6;365(14):1315-27 [21991953.001]
  • [Cites] Br J Dermatol. 2010 May;162(5):1088-92 [20199550.001]
  • [Cites] Clin Exp Allergy. 2009 Dec;39(12 ):1889-95 [19817751.001]
  • [Cites] Allergy. 2017 Jan;72 (1):146-163 [27322918.001]
  • [Cites] Br J Dermatol. 1994 Sep;131(3):406-16 [7918017.001]
  • [Cites] J Allergy Clin Immunol. 2009 Dec;124(6):1251-8.e23 [20004783.001]
  • [Cites] J Allergy Clin Immunol. 2014 Oct;134(4):800-7 [25282560.001]
  • [Cites] J Allergy Clin Immunol. 2007 Sep;120(3):565-9 [17655920.001]
  • [Cites] BMC Dermatol. 2012 Jul 27;12:11 [22839963.001]
  • [Cites] J Allergy Clin Immunol. 2004 May;113(5):832-6 [15131563.001]
  • [Cites] Clin Exp Allergy. 2004 Apr;34(4):520-6 [15080802.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2009 Nov;23(11):1267-72 [19508310.001]
  • (PMID = 28732519.001).
  • [ISSN] 1745-6215
  • [Journal-full-title] Trials
  • [ISO-abbreviation] Trials
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Atopic dermatitis / Barrier enhancement / Core outcomes / Eczema / Emollient / Filaggrin / Prevention / Protocol / Randomised controlled trial
  •  go-up   go-down


43. Baselga J, Schwartzberg LS, Petrenciuc O, Shan M, Gradishar WJ: Design of RESILIENCE: A phase (Ph) III trial comparing capecitabine (CAP) in combination with sorafenib (SOR) or placebo (PL) for treatment (tx) of locally advanced (adv) or metastatic HER2-negative breast cancer (BC). J Clin Oncol; 2011 May 20;29(15_suppl):TPS124

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most drug-related adverse events were grade 1/2 in severity with the exception of grade 3 hand-foot skin reaction/syndrome (HFSR/HFS) (44% in SOR+CAP vs 14% in PL+CAP).
  • Radiographic assessment is every 6 wk for the first 36 wk, and every 9 wk thereafter.
  • Secondary endpoints include overall survival, time to progression, overall response rate, duration of response (RECIST 1.1 criteria), and safety.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28022937.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Shen Y, Hsu C, Hsu C, Lin Z, Chen P, Shao Y, Huang T, Ding Y, Cheng A: A phase II study of sorafenib in combination with tegafur/uracil (UFT) for Asian patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol; 2009 May 20;27(15_suppl):4589

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We conducted a phase II study to evaluate the efficacy and safety of sorafenib plus low-dose UFT in advanced HCC patients (pts).
  • Tumor assessment was performed q8w by RECIST criteria.
  • Hand-foot skin reaction (HFSR), fatigue, and diarrhea were most common AEs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963091.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Sowada J, Lemoine L, Schön K, Hutzler C, Luch A, Tralau T: Toxification of polycyclic aromatic hydrocarbons by commensal bacteria from human skin. Arch Toxicol; 2017 Jun;91(6):2331-2341

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxification of polycyclic aromatic hydrocarbons by commensal bacteria from human skin.
  • This study now shows that readily isolable skin commensals transform B[a]P into a range of highly cyto- and genotoxic metabolites that are excreted in toxicologically relevant concentrations during growth.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2005 Jul 11;33(12):3799-811 [16009812.001]
  • [Cites] J Hazard Mater. 2009 Sep 30;169(1-3):492-7 [19414215.001]
  • [Cites] Arch Toxicol. 2016 Jun;90(6):1449-58 [26238291.001]
  • [Cites] Nat Rev Cancer. 2005 Feb;5(2):113-25 [15660110.001]
  • [Cites] Atmos Environ. 1969 Sep;3(5):565-72 [4187590.001]
  • [Cites] Science. 2009 Dec 18;326(5960):1694-7 [19892944.001]
  • [Cites] Appl Microbiol Biotechnol. 2006 Jul;71(4):522-32 [16317545.001]
  • [Cites] Environ Mol Mutagen. 2005 Mar-Apr;45(2-3):106-14 [15688365.001]
  • [Cites] EXS. 2009;99:151-79 [19157061.001]
  • [Cites] MBio. 2013 Oct 29;4(6):e00782-13 [24169577.001]
  • [Cites] Arch Toxicol. 2014 Dec;88(12):2135-90 [25370008.001]
  • [Cites] Environ Toxicol Chem. 2001 Mar;20(3):632-43 [11349866.001]
  • [Cites] FEMS Microbiol Lett. 2003 Jun 27;223(2):177-83 [12829283.001]
  • [Cites] Methods Enzymol. 1990;188:148-53 [2280701.001]
  • [Cites] J Hazard Mater. 2009 Sep 30;169(1-3):1-15 [19442441.001]
  • [Cites] Chem Res Toxicol. 2011 Oct 17;24(10 ):1653-67 [21916506.001]
  • [Cites] Environ Sci Pollut Res Int. 2015 Nov;22(21):16393-404 [25471715.001]
  • [Cites] FEMS Microbiol Ecol. 2014 Apr;88(1):129-39 [24372170.001]
  • [Cites] Crit Rev Microbiol. 2015;41(3):326-40 [24645635.001]
  • [Cites] Cell Mol Life Sci. 2015 Apr;72(8):1499-515 [25548803.001]
  • [Cites] Cell. 2016 May 5;165(4):801-11 [27153494.001]
  • [Cites] Science. 2009 May 29;324(5931):1190-2 [19478181.001]
  • [Cites] J Environ Monit. 2007 Sep;9(9):1001-8 [17726562.001]
  • [Cites] Toxicol Lett. 2013 Apr 12;218(2):97-104 [23391484.001]
  • [Cites] EXS. 2009;99:57-86 [19157058.001]
  • [Cites] Carcinogenesis. 1998 Oct;19(10):1847-53 [9806168.001]
  • [Cites] Environ Monit Assess. 2008 Apr;139(1-3):107-18 [17566864.001]
  • [Cites] Biomed Chromatogr. 2016 Mar;30(3):474-83 [26230188.001]
  • [Cites] PLoS One. 2016 Jan 15;11(1):e0147239 [26771904.001]
  • [Cites] Cell. 2012 Mar 16;148(6):1258-70 [22424233.001]
  • [Cites] Drug Metab Pharmacokinet. 2006 Aug;21(4):257-76 [16946553.001]
  • [Cites] Expert Opin Drug Metab Toxicol. 2015 Mar;11(3):411-25 [25476418.001]
  • [Cites] Chem Res Toxicol. 1995 Jan-Feb;8(1):136-42 [7703357.001]
  • [Cites] FEMS Microbiol Rev. 2008 Nov;32(6):927-55 [18662317.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):908-15 [10706104.001]
  • [Cites] Mucosal Immunol. 2012 Sep;5(5):567-79 [22617837.001]
  • [Cites] Exp Dermatol. 2012 May;21(5):364-9 [22509834.001]
  • [Cites] Curr Opin Chem Biol. 2013 Jun;17(3):379-84 [23680493.001]
  • [Cites] Environ Mol Mutagen. 2016 Apr;57(3):229-35 [26919089.001]
  • [Cites] Biochemistry. 1977 Apr 5;16(7):1467-73 [191070.001]
  • [Cites] Toxicol Sci. 2013 Feb;131(2):351-9 [23148024.001]
  • (PMID = 28378121.001).
  • [ISSN] 1432-0738
  • [Journal-full-title] Archives of toxicology
  • [ISO-abbreviation] Arch. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; Benzo[a]pyrene / Cytotoxicity / Genotoxicity / Microbiome / PAHs / Polycyclic aromatic hydrocarbons / Toxification
  •  go-up   go-down


46. Dall' Oglio F, Tedeschi A, Fusto CM, Lacarrubba F, Dinotta F, Micali G: A novel cosmetic antifungal/anti-inflammatory topical gel for the treatment of mild to moderate seborrheic dermatitis of the face: an open-label trial utilizing clinical evaluation and erythema-directed digital photography. G Ital Dermatol Venereol; 2017 Oct;152(5):436-440
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Advanced digital photography, equipped with technology able to provide a detailed evaluation of red skin components corresponding to vascular flare (erythema-directed digital photography), is a useful tool for evaluation of erythema in patients affected by inflammatory dermatoses.
  • The aim of this study was to assess the efficacy and safety of a new cosmetic topical gel containing piroctone olamine, lactoferrin, glycero-phospho-inositol, and Aloe vera for the treatment of facial seborrheic dermatitis by clinical and advanced digital photography evaluation.
  • Finally, at baseline and at the end of the study, IGA (Investigator Global Assessment) was performed using a 5-point severity scale (from 0 = worsening to 4 = excellent response).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28121079.001).
  • [ISSN] 1827-1820
  • [Journal-full-title] Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia
  • [ISO-abbreviation] G Ital Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


47. Duvic M, Ziari S, Olsen EA, Foss FM: Phase 1-2 multi-center study of intravenous Bcx-1777 in patients with refractory cutaneous T-cell lymphoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):6733

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 6733 Background: Cutaneous T-cell lymphomas (CTCL) including the leukemic variant, Sezary Syndrome (SS) are incurable extra-nodal non-Hodgkin's lymphomas caused by accumulation of skin homing T-cells.
  • Clinical response was determined each course using a weighted composite of disease assessment from baseline.
  • Safety visits were conducted weekly.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014492.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Helmer E, Watling M, Jones E, Tytgat D, Jones M, Allen R, Payne A, Koch A, Healy E: First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases. Eur J Clin Pharmacol; 2017 May;73(5):581-591
MedlinePlus Health Information. consumer health - Psoriasis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These studies aimed to investigate the safety, tolerability and PK profile of seletalisib, a selective inhibitor of PI3Kδ in humans.
  • Pharmacodynamic effects on markers of inflammation were assessed via changes in ex vivo basophil degranulation and histological assessment of psoriatic skin biopsies.
  • No safety concerns or dose-limiting toxicities were identified (Study-1).
  • Pharmacodynamic findings demonstrated ex vivo inhibition of basophil degranulation, improvements in histological assessment of skin biopsies and other markers of psoriatic biology and preliminary evidence of target engagement in psoriatic skin tissue.
  • CONCLUSIONS: Seletalisib safety, tolerability and pharmacokinetic/pharmacodynamic profiles support its continued clinical development in immune-inflammatory diseases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Allergy Clin Immunol. 1976 Dec;58(6):676-82 [993482.001]
  • [Cites] Cell Death Dis. 2012 Jun 28;3:e334 [22739986.001]
  • [Cites] Am J Clin Dermatol. 2014 Oct;15(5):379-85 [25027461.001]
  • [Cites] Blood. 2010 Mar 18;115(11):2203-13 [20081091.001]
  • [Cites] Curr Opin Pharmacol. 2015 Aug;23:82-91 [26093105.001]
  • [Cites] Int J Rheum Dis. 2014 May;17(4):359-68 [24460872.001]
  • [Cites] J Invest Dermatol. 2009 Jan;129(1):79-88 [18633443.001]
  • [Cites] Cell Signal. 2011 Apr;23(4):603-8 [20940048.001]
  • [Cites] J Autoimmun. 2011 May;36(3-4):278-87 [21396797.001]
  • [Cites] J Invest Dermatol. 2007 Oct;127(10):2445-52 [17495954.001]
  • [Cites] Ann N Y Acad Sci. 2013 Mar;1280:24-6 [23551098.001]
  • [Cites] J Immunol. 2012 Nov 1;189(9):4612-20 [23024273.001]
  • [Cites] J Invest Dermatol. 2008 May;128(5):1064-7 [18408745.001]
  • [Cites] Trends Immunol. 2007 Feb;28(2):80-7 [17208518.001]
  • [Cites] Open Rheumatol J. 2012;6:245-58 [23028409.001]
  • [Cites] Br J Dermatol. 2014 Jan;170(1):59-65 [24117368.001]
  • [Cites] J Invest Dermatol. 2014 Jan;134(1):268-71 [23812303.001]
  • [Cites] Arch Dermatol Res. 2011 Dec;303(10):691-705 [21863252.001]
  • [Cites] Rheumatology (Oxford). 2015 Feb;54(2):219-30 [25342375.001]
  • [Cites] Rheumatology (Oxford). 2012 Mar;51(3):552-6 [22120603.001]
  • [Cites] J Immunol. 2008 Feb 15;180(4):2538-44 [18250464.001]
  • [Cites] N Engl J Med. 2009 Jul 30;361(5):496-509 [19641206.001]
  • [Cites] Front Immunol. 2012 Aug 23;3:256 [22936933.001]
  • [Cites] Blood. 2007 Oct 15;110(8):2940-7 [17626838.001]
  • [Cites] J Autoimmun. 2015 Dec;65:1-18 [26515757.001]
  • (PMID = 28160012.001).
  • [ISSN] 1432-1041
  • [Journal-full-title] European journal of clinical pharmacology
  • [ISO-abbreviation] Eur. J. Clin. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Placebos; 0 / Pyridines; 0 / Quinolines; 0 / seletalisib; EC 2.7.1.- / Phosphatidylinositol 3-Kinases
  • [Keywords] NOTNLM ; Inflammatory / PI3Kδ / Pharmacodynamic / Pharmacokinetic / Phase I / Seletalisib
  •  go-up   go-down


49. Rodrigues AM, Sniehotta FF, Birch-Machin MA, Araujo-Soares V: Aware, motivated and striving for a 'safe tan': an exploratory mixed-method study of sun-protection during holidays. Health Psychol Behav Med; 2017;5(1):276-298

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • <b>Methods:</b> Seventeen participants aged 21-62 years old, recruited from community settings took part in individual face-to-face semi-structured interviews, completed sun sensitivity questions and an objective assessment of sunscreen use.
  • They are aware of the need to protect from solar UVR, but the motive for a safe tan, the overreliance on sunscreen, the overestimation of the safe sun-exposure time for their skin type and the insufficient application of sunscreen leaves holidaymakers motivated to protect their skin at significant risk of overexposure, sunburn and skin cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Dermatol. 2016 Dec;175(6):1401-1403 [27292412.001]
  • [Cites] Int J Behav Nutr Phys Act. 2015 Feb 21;12:25 [25889481.001]
  • [Cites] Pediatrics. 2002 Jun;109(6):1009-14 [12042536.001]
  • [Cites] Health Psychol. 2000 Sep;19(5):469-78 [11007155.001]
  • [Cites] Health Educ Res. 2011 Feb;26(1):39-52 [21059798.001]
  • [Cites] J Skin Cancer. 2012;2012:480985 [22649734.001]
  • [Cites] Health Educ Behav. 2001 Jun;28(3):290-305 [11380050.001]
  • [Cites] Implement Sci. 2012 Apr 24;7:35 [22531601.001]
  • [Cites] Br J Cancer. 2011 Dec 6;105 Suppl 2:S66-9 [22158324.001]
  • [Cites] J Natl Cancer Inst. 1998 Dec 16;90(24):1873-80 [9862624.001]
  • [Cites] Eur J Public Health. 2006 Oct;16(5):492-7 [16195355.001]
  • [Cites] J Am Acad Dermatol. 2002 May;46(5):683-9 [12004307.001]
  • [Cites] Psychooncology. 2016 Feb;25(2):158-63 [26101815.001]
  • [Cites] Br J Dermatol. 2009 Nov;161 Suppl 3:116-23 [19775367.001]
  • [Cites] Br J Dermatol. 2009 Nov;161 Suppl 3:25-7 [19775353.001]
  • [Cites] Health Psychol. 2003 Mar;22(2):199-209 [12683740.001]
  • [Cites] Health Educ Res. 2010 Feb;25(1):162-82 [19858077.001]
  • [Cites] Arch Dermatol. 2010 Sep;146(9):979-84 [20855696.001]
  • [Cites] J Cosmet Dermatol. 2004 Apr;3(2):62-8 [17147557.001]
  • [Cites] Psychol Health. 2013;28(5):477-94 [23252669.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2015 Feb;29 Suppl 2:6-10 [25639926.001]
  • [Cites] J Behav Med. 2009 Dec;32(6):532-44 [19653089.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2011 Dec;20(12):2583-93 [22016471.001]
  • [Cites] Health Educ J. 2009 Sep;68(3):232-243 [22707763.001]
  • [Cites] Ann Behav Med. 2013 Apr;45(2):224-38 [23229160.001]
  • [Cites] BMC Public Health. 2011 Aug 31;11:679 [21884577.001]
  • [Cites] Health Educ Behav. 2003 Feb;30(1):29-43 [12564666.001]
  • [Cites] J Clin Oncol. 2011 Jan 20;29(3):257-63 [21135266.001]
  • [Cites] Health Educ Res. 2005 Oct;20(5):579-85 [15644381.001]
  • [Cites] Psychol Health. 2010 Dec;25(10):1229-45 [20204937.001]
  • [Cites] Am J Prev Med. 2004 Dec;27(5):422-66 [15556744.001]
  • [Cites] J Psychol. 1975 Sep;91(1):93-114 [28136248.001]
  • [Cites] Arch Dermatol. 2008 Nov;144(11):1449-55 [19015419.001]
  • [Cites] Qual Saf Health Care. 2005 Feb;14 (1):26-33 [15692000.001]
  • [Cites] J Behav Med. 2013 Apr;36(2):109-23 [22460361.001]
  • [Cites] J Public Health (Oxf). 2014 Mar;36(1):56-64 [23365261.001]
  • [Cites] Int J Environ Res Public Health. 2016 Jan 19;13(1):null [26797627.001]
  • [Cites] Photochem Photobiol Sci. 2013 Jan;12(1):190-6 [23023728.001]
  • [Cites] Cancer Causes Control. 2011 Jul;22(7):1067-71 [21637987.001]
  • [Cites] Health Psychol. 1988;7(4):355-86 [3049068.001]
  • [Cites] J Invest Dermatol. 2007 Jan;127(1):41-8 [17068486.001]
  • [Cites] Pigment Cell Melanoma Res. 2010 Feb;23(1):57-63 [19968819.001]
  • [Cites] Br J Health Psychol. 2013 Feb;18(1):182-217 [22989352.001]
  • [Cites] Arch Dermatol. 1988 Jun;124(6):869-71 [3377516.001]
  • [Cites] J Behav Med. 1997 Apr;20(2):207-22 [9144041.001]
  • [Cites] BMJ Open. 2013 Jun 28;3(6):null [23811173.001]
  • [Cites] Am J Health Behav. 2004 Nov-Dec;28(6):531-41 [15569587.001]
  • (PMID = 28670503.001).
  • [ISSN] 2164-2850
  • [Journal-full-title] Health psychology and behavioral medicine
  • [ISO-abbreviation] Health Psychol Behav Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Sun-safety / interview / public health / skin cancer / tanning
  •  go-up   go-down


50. Cunningham G, Belkoff L, Brock G, Efros M, Gittelman M, Carrara D, Neijber A, Ando M, Mitchel J: EFFICACY AND SAFETY OF A NEW TOPICAL TESTOSTERONE REPLACEMENT GEL THERAPY FOR THE TREATMENT OF MALE HYPOGONADISM. Endocr Pract; 2017 May;23(5):557-565
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EFFICACY AND SAFETY OF A NEW TOPICAL TESTOSTERONE REPLACEMENT GEL THERAPY FOR THE TREATMENT OF MALE HYPOGONADISM.
  • This study aimed to evaluate the efficacy and safety of testosterone gel 2% (Tgel) over 90 days.
  • Safety endpoints were adverse events (AEs), laboratory parameters, and vital signs.
  • Tgel had a favorable local skin tolerability profile.
  • Symptoms of testosterone deficiency improved with few safety concerns.
  • ABBREVIATIONS: AE = adverse event C<sub>ave(0-24)</sub> = average testosterone concentration CI = confidence interval C<sub>max</sub> = maximum concentration IIEF = International Index of Erectile Function MAF = Multidimensional Assessment of Fatigue PK = pharmacokinetic PSA = prostate-specific antigen SAE = serious adverse event SF-12 = Short Form 12 Health Survey Tgel = testosterone gel 2% T<sub>max</sub> = time to achieve maximum concentration TRT = testosterone replacement therapy.

  • MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28225313.001).
  • [ISSN] 1530-891X
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gels; 3XMK78S47O / Testosterone
  •  go-up   go-down


51. Palmieri C, Stein RC, Liu X, Hudson E, Nicholas H, Sasano H, Guestini F, Holcombe C, Barrett S, Kenny L, Reed S, Lim A, Hayward L, Howell S, Coombes RC, IRIS trial participants: IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients. Breast Cancer Res Treat; 2017 Sep;165(2):343-353
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We performed a multicentre, open label phase II trial of the addition of Irosustat to a first-line aromatase inhibitor (AI) in patients with advanced BC to evaluate the safety of the combination and to test the hypothesis that the addition of Irosustat to AI may further suppress estradiol levels and result in clinical benefit.
  • Secondary endpoints included safety, tolerability, and pharmacodynamic end points.
  • RESULTS: Twenty-seven women were recruited, four discontinued treatment without response assessment.
  • The most frequently reported grade 3/4 toxicities were dry skin (28%), nausea (13%), fatigue (13%), diarrhoea (8%), headache (7%), anorexia (7%) and lethargy (7%).
  • CONCLUSIONS: The addition of Irosustat to aromatase inhibitor therapy resulted in clinical benefit with an acceptable safety profile.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Rev. 2009 Jun;30(4):343-75 [19389994.001]
  • [Cites] Clin Cancer Res. 2016 Mar 1;22(5):1130-7 [26500237.001]
  • [Cites] N Engl J Med. 2012 Feb 9;366(6):520-9 [22149876.001]
  • [Cites] Br J Cancer. 1990 Oct;62(4):679-83 [2145964.001]
  • [Cites] Clin Cancer Res. 2012 Jun 15;18(12 ):3305-15 [22550166.001]
  • [Cites] Breast Cancer Res Treat. 2010 Apr;120(3):639-48 [20151319.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2762-70 [12782580.001]
  • [Cites] Steroids. 2016 Jan;105:50-8 [26666359.001]
  • [Cites] Breast Cancer Res Treat. 1989 Jan;13(1):61-9 [2495831.001]
  • [Cites] N Engl J Med. 2016 Nov 3;375(18):1738-1748 [27717303.001]
  • [Cites] Cancer Res. 1981 Nov;41(11 Pt 1):4720-6 [6458355.001]
  • [Cites] Breast Cancer Res Treat. 2013 Jun 25;140(1):73-82 [23797179.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2001 Oct;6(4):407-17 [12013530.001]
  • [Cites] Int J Cancer. 2000 Jan 20;89(1):39-43 [10719729.001]
  • [Cites] Breast Cancer Res Treat. 2009 May;115(2):289-96 [18521740.001]
  • [Cites] Nat Rev Clin Oncol. 2010 Feb;7(2):72-4 [20118974.001]
  • [Cites] J Steroid Biochem Mol Biol. 2000 Dec 31;75(4-5):253-8 [11282279.001]
  • [Cites] Mol Cell Endocrinol. 2014 Jan 25;382(1):695-723 [23933149.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4026-9 [10945602.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 2):1008s-1012s [16467117.001]
  • [Cites] Surgery. 2001 Dec;130(6):947-53 [11742322.001]
  • [Cites] Anticancer Res. 2011 Apr;31(4):1367-72 [21508387.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Aug;88(8):3902-12 [12915686.001]
  • [Cites] Lancet Oncol. 2013 Sep;14 (10 ):989-98 [23902874.001]
  • [Cites] Cancer Res. 1986 Oct;46(10):4933-7 [2944574.001]
  • [Cites] Trends Endocrinol Metab. 1993 Mar;4(2):69-74 [18407137.001]
  • [Cites] Br J Surg. 2014 Jul;101(8):939-48 [24687409.001]
  • [Cites] Breast Cancer Res Treat. 2012 Aug;134(3):1027-39 [22456984.001]
  • [Cites] N Engl J Med. 2015 Jul 16;373(3):209-19 [26030518.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4864-9 [10519397.001]
  • [Cites] Breast Cancer. 1999 Oct 25;6(4):298-300 [11091733.001]
  • [Cites] J Steroid Biochem Mol Biol. 2000 Jul-Aug;73(5):225-35 [11070351.001]
  • [Cites] J Clin Invest. 1972 Apr;51(4):1020-33 [5014608.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1585-92 [16533785.001]
  • [Cites] Lancet. 1978 Nov 18;2(8099):1097 [82112.001]
  • (PMID = 28612226.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Aromatase / Breast cancer / Endocrine therapy / Sulfatase
  •  go-up   go-down


52. Adjadj L, SidAhmed-Mezi M, Mondoloni M, Meningaud JP, Hersant B: Assessment of the Efficacy of Cryolipolysis on Saddlebags: A Prospective Study of 53 Patients. Plast Reconstr Surg; 2017 Jul;140(1):50-57

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of the Efficacy of Cryolipolysis on Saddlebags: A Prospective Study of 53 Patients.
  • The main objective of this study was to demonstrate the efficacy, patient tolerance, and safety of cryolipolysis on the saddlebags.
  • Reversible skin changes such as postprocedure postinflammatory hyperpigmentation were observed in 8.33 percent of patients.
  • A substantial risk of skin lesions, including postinflammatory hyperpigmentation that resolved after a few months, was observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Plast Reconstr Surg. 2017 Jul;140(1):58-59 [28654589.001]
  • (PMID = 28654588.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Makino ET, Kadoya K, Sigler ML, Hino PD, Mehta RC: Development and Clinical Assessment of a Comprehensive Product for Pigmentation Control in Multiple Ethnic Populations. J Drugs Dermatol; 2016 Dec 01;15(12):1562-1570
Hazardous Substances Data Bank. HYDROQUINONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development and Clinical Assessment of a Comprehensive Product for Pigmentation Control in Multiple Ethnic Populations.
  • OBJECTIVES: To develop a comprehensive product (LYT2) that affects all major biological pathways controlling pigmentation and test for clinical efficacy and safety in different ethnic populations.
  • METHODS: A thorough analysis of biological pathways was used to identify ingredient combinations for LYT2 that provided optimal melanin reduction in a 3-D skin model.
  • The outcome clearly shows greater pigmentation control with LYT2 compared to other HQ-free products in skin tissue models and earlier control in clinical studies compared to 4% HQ.
  • [MeSH-major] Ethnic Groups. Hydroquinones / administration & dosage. Melanins / antagonists & inhibitors. Skin Lightening Preparations / administration & dosage. Skin Pigmentation / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28095579.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hydroquinones; 0 / Melanins; 0 / Skin Lightening Preparations; XV74C1N1AE / hydroquinone
  •  go-up   go-down


54. Cohn AL, Smith DA, Neubauer MA, Houston G, Khandelwal P, Wiggans RG, Zhang K, Yassine M: Results from panitumumab (pmab) regimen evaluation in colorectal cancer to estimate primary response to treatment (PRECEPT): Second-line treatment with pmab and FOLFIRI by tumor KRAS status. J Clin Oncol; 2009 May 20;27(15_suppl):4067

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Efficacy (objective response, progression-free survival [PFS], and overall survival [OS]) and safety were evaluated by KRAS status.
  • RESULTS: In an interim analysis (May 2008) of 115 pts who had received ≥ 1 dose of pmab, 109 pts had known KRAS status (59% had tumors with wild-type [WT] KRAS, 41% had mutant [MT] KRAS tumors), and 102 pts had the opportunity to have their first tumor assessment.
  • Most common AEs were skin-related toxicities (86% of pts), diarrhea (72%), and nausea (53%); there was no evidence that incidence of AEs was related to KRAS status.
  • Pmab had a safety profile consistent with other FOLFIRI + pmab trials.
  • Final efficacy and safety data will be presented.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961606.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Boireau C, Dufour B, Praud A: The importance of communication in promoting voluntary participation in an experimental trial: A qualitative study based on the assessment of the gamma-interferon test for the diagnosis of bovine tuberculosis in France. PLoS One; 2017;12(10):e0185799

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The importance of communication in promoting voluntary participation in an experimental trial: A qualitative study based on the assessment of the gamma-interferon test for the diagnosis of bovine tuberculosis in France.
  • An experimental protocol, validated by the European Commission, was developed in France to assess the ability of the gamma-interferon test in terms of accuracy to replace the second intradermal skin test in cases of suspected bovine tuberculosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28973018.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Crawford J, Sandler AB, Hammond LA, Schiller J, Belani C, Kozloff M, Johnson D, Fleishman A, Lee S, Takeshita K: ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2004 Jul 15;22(14_suppl):7083

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is a report of results from part 1 of a 2-part, phase 2 trial to evaluate the efficacy, safety, and pharmacokinetics (PK) of ABX-EGF in combination with paclitaxel and carboplatin for advanced NSCLC.
  • One pt (5%) had a confirmed complete response (1.0 mg/kg) and 4 pts (21%) had partial responses (2 at 2.0 mg/kg and 2 at 2.5 mg/kg) by investigator assessment.
  • The most common adverse event (AE) was skin rash (89% overall; 83%, 100%, and 83% in the 1.0, 2.0, and 2.5 mg/kg groups).
  • The incidence of grade 3 skin rash did not appear to increase with dose (17% at 1.0 mg/kg, 29% at 2.0 mg/kg, and 0% at 2.5 mg/kg).
  • Four pts (1 at 1.0 mg/kg and 3 at 2.0 mg/kg) had ABX-EGF dosing interrupted or reduced because of skin toxicities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016137.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Hojerová J, Peráčková Z, Beránková M: Margin of safety for two UV filters estimated by in vitro permeation studies mimicking consumer habits: Effects of skin shaving and sunscreen reapplication. Food Chem Toxicol; 2017 May;103:66-78
Hazardous Substances Data Bank. 2-HYDROXY-4-METHOXYBENZOPHENONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Margin of safety for two UV filters estimated by in vitro permeation studies mimicking consumer habits: Effects of skin shaving and sunscreen reapplication.
  • Sunscreens are intended to work on the skin.
  • The potential for systemic absorption of Benzophenone-3 (BP3, 10%) and Ethylhexyl Triazone (EHT, 5%) in a silicone-based water-in-oil emulsion was assessed in vitro using a full-thickness porcine-ear skin mimicking in-use conditions.
  • (ii) on the whole-body skin, was (i) 136 and 30;.
  • Skin shaving increased BP3 and EHT bioavailability 1.38 and 1.80-fold, respectively.
  • Margin of Safety values were estimated according to guidelines applicable for European Union.
  • For three realistic exposure scenarios, MoS of 48, 34 and 34 for BP3 in the sunscreen applied on the whole-body indicate some concerns regarding the safety for consumers (MoS<100).
  • [MeSH-major] Benzophenones / adverse effects. Drug Evaluation, Preclinical / methods. Skin / drug effects. Skin Absorption / drug effects. Sunscreening Agents / adverse effects

  • MedlinePlus Health Information. consumer health - Sun Exposure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28216167.001).
  • [ISSN] 1873-6351
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzoates; 0 / Benzophenones; 0 / Emulsions; 0 / Sunscreening Agents; 0 / Triazines; 88122-99-0 / octyl triazone; 95OOS7VE0Y / oxybenzone
  • [Keywords] NOTNLM ; Benzophenone-3 / Ethylhexyl triazone / Human exposure assessment / Margin of safety / Shaving skin / Systemic exposure dose
  •  go-up   go-down


58. Park M, Naidoo AA, Burns A, Choi JK, Gatfield KM, Vidgeon-Hart M, Bae IH, Lee CS, Choi G, Powell AJ, Park YH, Fagg R: Do TRPV1 antagonists increase the risk for skin tumourigenesis? A collaborative in vitro and in vivo assessment. Cell Biol Toxicol; 2017 Aug 16;
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do TRPV1 antagonists increase the risk for skin tumourigenesis? A collaborative in vitro and in vivo assessment.
  • However, little is known about the long-term physiologic effects of TRPV1 blockade in the skin.
  • In vitro and in vivo studies suggested that the potent TRPV1 competitive antagonist AMG-9810 promoted proliferation in N/TERT1 cells (telomerase-immortalised primary human keratinocytes 1) and tumour development in mouse skin that was mediated through EGFR/Akt/mTOR signalling.
  • We attempted to reproduce the reported in vitro and in vivo findings to further explore this hypothesis to understand the underlying mechanism and the risk associated with TRPV1 antagonism in the skin.
  • We were also unable to demonstrate skin tumour promotion or underlying molecular mechanisms involved in the EGFR/Akt/mTOR signalling pathway in a single-dose and two-stage carcinogenesis mouse study treated with TRPV1 antagonists.
  • In conclusion, our data suggest that inhibiting the pharmacological function of TRPV1 in skin by specific antagonists has not been considered to be indicative of skin tumour development.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28815372.001).
  • [ISSN] 1573-6822
  • [Journal-full-title] Cell biology and toxicology
  • [ISO-abbreviation] Cell Biol. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; EGFR/Akt/mTOR / Human keratinocytes / Skin tumour / TRPV1
  •  go-up   go-down


59. Avonto C, Wang M, Chittiboyina AG, Vukmanovic S, Khan IA: Chemical stability and in chemico reactivity of 24 fragrance ingredients of concern for skin sensitization risk assessment. Toxicol In Vitro; 2017 Sep 16;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemical stability and in chemico reactivity of 24 fragrance ingredients of concern for skin sensitization risk assessment.
  • Twenty-four pure fragrance ingredients have been identified as potential concern for skin sensitization.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017. Published by Elsevier Ltd.
  • (PMID = 28927722.001).
  • [ISSN] 1879-3177
  • [Journal-full-title] Toxicology in vitro : an international journal published in association with BIBRA
  • [ISO-abbreviation] Toxicol In Vitro
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; DCYA / Fragrance ingredients / In chemico methods / Skin sensitization / Stability studies
  •  go-up   go-down


60. Cheng CY, Huang YL, Lee MC, Chang SL, Lin YF, Hu S: Pulsed alexandrite laser for treatment of melasma in Asian patients. J Cosmet Laser Ther; 2017 Aug;19(4):210-214

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present study was conducted to evaluate the efficacy and safety of pulsed alexandrite laser for the treatment of melasma.
  • The severity of melasma was evaluated by a blinded dermatologist, using the Modified Melasma Area and Severity Index (MMASI), and by patient assessment, using a visual analogue scale, at baseline, before each treatment, and at the 1-month and 3-month follow-up visits after the last treatment.
  • The treatments were well tolerated with only mild skin reaction.
  • CONCLUSION: In the present study, we demonstrated that the pulsed alexandrite laser is safe and effective to treat melasma in Asian skin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28151024.001).
  • [ISSN] 1476-4180
  • [Journal-full-title] Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology
  • [ISO-abbreviation] J Cosmet Laser Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Alexandrite laser / Asian / melasma
  •  go-up   go-down


61. Jones K, Johnson PD, Baldwin PEJ, Coldwell M, Cooke J, Keen C, Harding AH, Smith D, Cocker J: Exposure to Diisocyanates and Their Corresponding Diamines in Seven Different Workplaces. Ann Work Expo Health; 2017 Apr 01;61(3):383-393

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because of this, any exposure to the diamines themselves released during the industrial process could confound the assessment of diisocyanate exposure.
  • This paper reports an initial assessment of the extent of diamine formation and exposure during different processes involving diisocyanates including casting, grouting, core making, spray painting, foam blowing, and floor screeding.
  • Some non-aerosol processes gave rise to substantial diamine levels in urine (in exceedance of international guidance values, >5 µmol mol-1 creatinine) despite airborne levels being well within occupational exposure limits (20 µg m-3 total NCO in Great Britain); measurement data and statistical modelling indicated that skin absorption was the most likely exposure route.
  • It also demonstrates the potential for substantial skin absorption of diisocyanates in certain processes such as floor screeding and foam production.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Crown Copyright 2017.
  • (PMID = 28355438.001).
  • [ISSN] 2398-7316
  • [Journal-full-title] Annals of work exposures and health
  • [ISO-abbreviation] Ann Work Expo Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; NCO / diamines / diisocyanates / floor screeding / foam blowing / skin absorption
  •  go-up   go-down


62. Jankowska A, Czerczak S, Kupczewska-Dobecka M: [Assessment of predictive dermal exposure to chemicals in the work environment]. Med Pr; 2017 Jun 27;68(4):557-569

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Assessment of predictive dermal exposure to chemicals in the work environment].
  • Assessment of dermal exposure to chemicals in the work environment is problematic, mainly as a result of the lack of measurement data on occupational exposure to chemicals.
  • Due to common prevalence of occupational skin exposure and its health consequences it is necessary to look for efficient solutions allowing for reliable exposure assessment.
  • This paper presents examples of models to assist the employer in the the assessment of occupational exposure associated with the skin contact with chemicals, developed in European Union (EU) countries, as well as in countries outside the EU.
  • Based on the literature data dermal exposure models EASE (Estimation and Assessment of Substance Exposure), COSHH Essentials (Control of Substances Hazardous to Health Regulations), DREAM (Dermal Exposure Assessment Method), Stoffenmanager , ECETOC TRA (European Centre for Ecotoxicology and Toxicology of Chemicals Targeted Risk Assessment), MEASE (Metal's EASE), PHED (Pesticide Handlers Exposure Database), DERM (Dermal Exposure Ranking Method) and RISKOFDERM (Risk Assessment of Occupational Dermal Exposure to Chemicals) were briefly described.
  • Problem of full work shift dermal exposure assessment is described.
  • An example of exposure assessment using RISKOFDERM and effectiveness evaluation to date were also presented.
  • When no measurements are available, RISKOFDERM allows dermal exposure assessment and thus can improve the risk assessment quality and effectiveness of dermal risk management.
  • Na podstawie danych literaturowych w artykule krótko opisano wybrane modele do szacowania narażenia dermalnego: EASE (Estimation and Assessment of Substance Exposure – oszacowanie i ocena narażenia na substancję), COSHH Essentials (Control of Substances Hazardous to Health Regulations – utrzymywanie pod kontrolą substancji niebezpiecznych dla zdrowia), DREAM (Dermal Exposure Assessment Method – metoda oceny narażenia dermalnego), Stoffenmanager, ECETOC TRA (European Centre for Ecotoxicology and Toxicology of Chemicals Targeted Risk Assessment – ukierunkowane szacowanie ryzyka Europejskiego Centrum ds.
  • Ekotoksykologii i Toksykologii Chemikaliów), MEASE (Metal’s EASE), PHED (Pesticide Handlers Exposure Database – baza danych na temat narażenia użytkowników pestycydów), DERM (Dermal Exposure Ranking Method – metoda rankingu narażenia dermalnego) i RISKOFDERM (Risk Assessment of Occupational Dermal Exposure to Chemicals – ocena ryzyka wynikającego z narażenia dermalnego na chemikalia).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] This work is available in Open Access model and licensed under a CC BY-NC 3.0 PL license.
  • (PMID = 28638154.001).
  • [ISSN] 0465-5893
  • [Journal-full-title] Medycyna pracy
  • [ISO-abbreviation] Med Pr
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Keywords] NOTNLM ; RISKOFDERM / dermal exposure / exposure assessment / occupational exposure / occupational hygiene / predictive models
  •  go-up   go-down


63. Wang CC, Lin YC, Wang SS, Shih C, Lin YH, Tung CW: SkinSensDB: a curated database for skin sensitization assays. J Cheminform; 2017;9:5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SkinSensDB: a curated database for skin sensitization assays.
  • Skin sensitization is an important toxicological endpoint for chemical hazard determination and safety assessment.
  • Prediction of chemical skin sensitizer had traditionally relied on data from rodent models.
  • The development of the adverse outcome pathway (AOP) and associated alternative in vitro assays have reshaped the assessment of skin sensitizers.
  • Current computational models to predict skin sensitization mainly based on in vivo assays without incorporating alternative in vitro assays.
  • However, there are few freely available databases integrating both the in vivo and the in vitro skin sensitization assays for development of AOP-based skin sensitization prediction models.
  • To facilitate the development of AOP-based prediction models, a skin sensitization database named SkinSensDB has been constructed by curating data from published AOP-related assays.
  • In addition to providing datasets for developing computational models, SkinSensDB is equipped with browsing and search tools which enable the assessment of new compounds for their skin sensitization potentials based on data from structurally similar compounds.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] PLoS One. 2016 Jun 07;11(6):e0155419 [27271321.001]
  • [Cites] Toxicol Sci. 2004 Oct;81(2):332-43 [15254333.001]
  • [Cites] Toxicol Sci. 2008 Mar;102(1):110-9 [17932397.001]
  • [Cites] Toxicol In Vitro. 2006 Aug;20(5):774-84 [16337770.001]
  • [Cites] Regul Toxicol Pharmacol. 2014 Aug;69(3):529-45 [24928565.001]
  • [Cites] Int J Mol Sci. 2009 Jul 17;10(7):3237-54 [19742136.001]
  • [Cites] J Cheminform. 2013 May 21;5:24 [23694746.001]
  • [Cites] Toxicology. 1995 Nov 20;103(1):63-73 [8525491.001]
  • [Cites] J Comput Chem. 2011 May;32(7):1466-74 [21425294.001]
  • [Cites] ALTEX. 2014;31(3):336-40 [24687303.001]
  • [Cites] Anal Chim Acta. 2006 Jul 21;572(2):272-82 [17723489.001]
  • [Cites] J Chem Inf Model. 2005 Jul-Aug;45(4):952-64 [16045289.001]
  • [Cites] J Appl Toxicol. 2016 Sep;36(9):1150-62 [26851134.001]
  • [Cites] Cell Mol Life Sci. 2012 Mar;69(5):763-81 [21997384.001]
  • [Cites] Chem Res Toxicol. 2007 Jan;20(1):114-28 [17226934.001]
  • [Cites] Regul Toxicol Pharmacol. 2014 Aug;69(3):371-9 [24813372.001]
  • [Cites] Food Chem Toxicol. 1992 Jan;30(1):65-9 [1544608.001]
  • [Cites] Crit Rev Toxicol. 2010 May;40(5):389-404 [20180632.001]
  • [Cites] Toxicol In Vitro. 2009 Apr;23(3):454-65 [19162165.001]
  • [Cites] Arch Toxicol. 2012 Aug;86(8):1273-95 [22707154.001]
  • [Cites] SAR QSAR Environ Res. 2013;24(12):1009-23 [23988224.001]
  • [Cites] Hum Exp Toxicol. 2015 Dec;34(12):1222-30 [26614809.001]
  • [Cites] Chem Res Toxicol. 2008 Jan;21(1):53-69 [18052130.001]
  • [Cites] Toxicol Appl Pharmacol. 2010 Jun 15;245(3):281-90 [20307559.001]
  • [Cites] Toxicol Appl Pharmacol. 2015 Apr 15;284(2):262-72 [25560674.001]
  • [Cites] Regul Toxicol Pharmacol. 2012 Aug;63(3):489-504 [22659254.001]
  • [Cites] Toxicol In Vitro. 2002 Dec;16(6):711-6 [12423654.001]
  • [Cites] Toxicol Sci. 2007 Oct;99(2):532-44 [17675333.001]
  • [Cites] J Comput Aided Mol Des. 2008 Jun-Jul;22(6-7):345-66 [18338230.001]
  • [Cites] Toxicol Sci. 2009 Nov;112(1):164-74 [19748994.001]
  • [Cites] Nucleic Acids Res. 2015 Jul 1;43(W1):W605-11 [25934803.001]
  • [Cites] Chem Res Toxicol. 2015 Oct 19;28(10):1975-86 [26382665.001]
  • (PMID = 28194231.001).
  • [ISSN] 1758-2946
  • [Journal-full-title] Journal of cheminformatics
  • [ISO-abbreviation] J Cheminform
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


64. Fiume MM, Heldreth B, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW, Andersen FA: Safety Assessment of Diethanolamine and Its Salts as Used in Cosmetics. Int J Toxicol; 2017 Sep/Oct;36(5_suppl2):89S-110S

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety Assessment of Diethanolamine and Its Salts as Used in Cosmetics.
  • The Cosmetic Ingredient Review (CIR) Expert Panel assessed the safety of diethanolamine and its salts as used in cosmetics.
  • Diethanolamine functions as a pH adjuster; the 16 salts included in this rereview reportedly function as surfactants, emulsifying agents, viscosity increasing agents, hair or skin conditioning agents, foam boosters, or antistatic agents.
  • Since data were not available for each individual ingredient, and since the salts dissociate freely in water, the Panel extrapolated from previous reports to support safety.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 29025348.001).
  • [ISSN] 1092-874X
  • [Journal-full-title] International journal of toxicology
  • [ISO-abbreviation] Int. J. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; cosmetics / diethanolamine / safety
  •  go-up   go-down


65. Attia A, Abushouk AI, Ahmed H, Gadelkarim M, Elgebaly A, Hassan Z, Abdel-Daim MM, Negida A: Safety and Efficacy of Brodalumab for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis. Clin Drug Investig; 2017 May;37(5):439-451
MedlinePlus Health Information. consumer health - Psoriasis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and Efficacy of Brodalumab for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis.
  • BACKGROUND: Psoriasis is an inflammatory skin disease that affects 2-3% of the worldwide population.
  • We aimed to evaluate the safety and efficacy of brodalumab as a therapeutic agent for moderate-to-severe psoriasis in a meta-analysis framework.
  • Analysis of secondary outcomes showed that brodalumab was superior to placebo in terms of static physician's global assessment (RR = 32.53, 95% CI 13.80-76.69) and psoriasis symptoms inventory scores (RR = 14.70, 95% CI 8.38-25.78).
  • CONCLUSION: Brodalumab showed an acceptable safety profile and a robust efficacy in the treatment of moderate-to-severe plaque psoriasis.

  • Genetic Alliance. consumer health - Psoriasis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28197901.001).
  • [ISSN] 1179-1918
  • [Journal-full-title] Clinical drug investigation
  • [ISO-abbreviation] Clin Drug Investig
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / IL17A protein, human; 0 / Interleukin-17; 0 / brodalumab
  •  go-up   go-down


66. Chu CH, Davis C: Urticarial Reaction to Ustekinumab During the Treatment of Plaque Psoriasis in a Hepatitis C-Positive Patient. Drug Saf Case Rep; 2017 Dec;4(1):9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After 10 months, she developed a round red rash on her skin diffusely on her body.
  • A Naranjo assessment score of 6 was obtained, indicating a probable relationship between the patient's urticaria and her use of ustekinumab.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2008 May 17;371(9625):1675-84 [18486740.001]
  • [Cites] Ann Dermatol. 2016 Apr;28(2):222-31 [27081271.001]
  • [Cites] Dermatol Reports. 2013 Sep 09;5(1):e2 [25386321.001]
  • [Cites] Int J Dermatol. 1996 Nov;35(11):797-9 [8915733.001]
  • [Cites] Acta Derm Venereol. 1995 Nov;75(6):482-3 [8651030.001]
  • [Cites] J Am Acad Dermatol. 2011 Jul;65(1):137-74 [21306785.001]
  • [Cites] J Invest Dermatol. 2013 Feb;133(2):377-85 [23014338.001]
  • [Cites] J Rheumatol. 1996 Jun;23(6):979-83 [8782126.001]
  • [Cites] J Am Acad Dermatol. 1998 Oct;39(4 Pt 2):S129-33 [9777790.001]
  • [Cites] J Am Acad Dermatol. 2014 Mar;70(3):512-6 [24388724.001]
  • [Cites] J Am Acad Dermatol. 1996 Aug;35(2 Pt 1):195-8 [8708019.001]
  • [Cites] Lancet. 2008 May 17;371(9625):1665-74 [18486739.001]
  • [Cites] J Rheumatol. 1999 Feb;26(2):370-2 [9972971.001]
  • (PMID = 28677075.001).
  • [ISSN] 2199-1162
  • [Journal-full-title] Drug safety - case reports
  • [ISO-abbreviation] Drug Saf Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


67. Nam CH, Park BC, Kim MH, Choi EH, Hong SP: The Efficacy and Safety of 660 nm and 411 to 777 nm Light-Emitting Devices for Treating Wrinkles. Dermatol Surg; 2017 Feb 09;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Efficacy and Safety of 660 nm and 411 to 777 nm Light-Emitting Devices for Treating Wrinkles.
  • BACKGROUND: Low-level light therapy (LLLT) using light-emitting diodes (LEDs) is considered to be helpful for skin regeneration and anti-inflammation.
  • OBJECTIVE: To evaluate the efficacy and safety of 2 types of LLLTs using 660 nm-emitting red LEDs and 411 to 777 nm-emitting white LEDs in the treatment of facial wrinkles.
  • RESULTS: In both groups treated with red and white LEDs, the wrinkle measurement from skin replica improved significantly from baseline at Week 12.
  • In the global assessment of the subjects, the mean improvement score of the red LED group was higher than that of the white LED group.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28195844.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Wang S, Mi J, Li Q, Jin R, Dong J: Fractional microplasma radiofrequency technology for non-hypertrophic post-burn scars in Asians: A prospective study of 95 patients. Lasers Surg Med; 2017 Aug;49(6):563-569

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among the various techniques, fractional microplasma radiofrequency technology (FMRT) has proven to be an effective treatment option for various types of scars and skin conditions such as rhytids, striae distensae, and hyperpigmentation.
  • OBJECTIVE: This prospective clinical trial was designed to evaluate the efficacy and safety of FMRT for treating non-hypertrophic post-burn scars in the Asian population.
  • The Patient and Observer Scar Assessment Scales (POSAS) [20] were used to evaluate changes in burn scars pre-and post-FMRT treatment.
  • No severe adverse events, such as acute skin infection, hypertrophic scarring, or depigmentation, were observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 Wiley Periodicals, Inc.
  • (PMID = 28220505.001).
  • [ISSN] 1096-9101
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; burns / cicatrix / lasers / micro-plasma / radiofrequency / scars
  •  go-up   go-down


69. Verner I, Kutscher TD: Clinical evaluation of the efficacy and safety of combined bipolar radiofrequency and optical energies vs. optical energy alone for the treatment of aging hands. Lasers Med Sci; 2017 Aug;32(6):1387-1392

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical evaluation of the efficacy and safety of combined bipolar radiofrequency and optical energies vs. optical energy alone for the treatment of aging hands.
  • This study evaluated the efficacy and safety of a novel technology, which combines bipolar radio frequency (RF) and optical energies for the cosmetic treatment of aging hands.
  • The objective of the study was to assess the efficacy, safety, tolerability, and patient satisfaction of combined bipolar radiofrequency and optical energies vs. optical energy alone for the treatment of aging hands.
  • Standardized clinical photographs were taken, and patient and investigator improvement assessment (Global Esthetic Improvement (GAI) scale), patient satisfaction, and tolerability were evaluated.
  • At the 1 and 3 months follow-up, skin laxity and pigmentation, investigator and patient improvement assessments, and satisfaction were significantly better in the hand treated with combined bipolar RF and IPL.
  • This study demonstrates the safety and efficacy of combining RF and optical energies for the esthetic improvement of aging hands.
  • Combined RF and IPL treatment was more efficient than IPL alone in improving skin pigmentation, skin laxity, and texture.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lasers Surg Med. 2003;32(2):120-8 [12561045.001]
  • [Cites] G Ital Dermatol Venereol. 2009 Jun;144(3):229-41 [19528905.001]
  • [Cites] J Drugs Dermatol. 2005 Mar-Apr;4(2):181-6 [15776775.001]
  • [Cites] Dermatol Surg. 2005 Sep;31(9 Pt 2):1211-7; discussion 1217 [16176773.001]
  • [Cites] J Cosmet Laser Ther. 2012 Oct;14(5):208-11 [23016529.001]
  • [Cites] J Clin Aesthet Dermatol. 2010 Dec;3(12):22-30 [21203352.001]
  • [Cites] Ann Plast Surg. 2010 May;64(5):526-9 [20354432.001]
  • [Cites] J Cosmet Laser Ther. 2012 Aug;14(4):179-83 [22658062.001]
  • [Cites] Dermatol Surg. 2000 Sep;26(9):835-42; discussion 843 [10971556.001]
  • [Cites] J Am Acad Dermatol. 2008 May;58(5):719-37; quiz 738-40 [18423256.001]
  • [Cites] Semin Cutan Med Surg. 2002 Dec;21(4):238-50 [12512647.001]
  • [Cites] Dermatol Clin. 2009 Oct;27(4):491-9, vii [19850198.001]
  • [Cites] Aesthetic Plast Surg. 2009 May;33(3):283-94 [19437070.001]
  • [Cites] J Cosmet Laser Ther. 2005 Mar;7(1):11-5 [16020210.001]
  • [Cites] J Drugs Dermatol. 2006 Sep;5(8):731-8 [16989187.001]
  • [Cites] Lasers Surg Med. 2009 Sep;41(7):473-8 [19708063.001]
  • [Cites] J Drugs Dermatol. 2009 Nov;8(11 Suppl):s9-13 [19916261.001]
  • [Cites] Dermatol Surg. 2002 Dec;28(12):1115-9 [12472489.001]
  • [Cites] Dermatol Surg. 2012 Nov;38(11):1765-76 [22913399.001]
  • [Cites] J Cutan Laser Ther. 2000 Jun;2(2):59-61 [11360318.001]
  • [Cites] Semin Cutan Med Surg. 2003 Jun;22(2):115-23 [12877230.001]
  • [Cites] J Cosmet Dermatol. 2002 Oct;1(3):142-3 [17147714.001]
  • [Cites] Dermatol Surg. 2001 Jul;27(7):627-31; discussion 632 [11442612.001]
  • [Cites] Lasers Surg Med. 2005 Sep;37(3):179-85 [16175631.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2006 Oct;20(9):1070-5 [16987260.001]
  • (PMID = 28643046.001).
  • [ISSN] 1435-604X
  • [Journal-full-title] Lasers in medical science
  • [ISO-abbreviation] Lasers Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Bipolar radiofrequency / Intense pulsed light / Laser / Noninvasive skin rejuvenation / Photo-damage / Pigmentary disorders
  •  go-up   go-down


70. Greveling K, Prens EP, Liu L, van Doorn MBA: Non-invasive anaesthetic methods for dermatological laser procedures: a systematic review. J Eur Acad Dermatol Venereol; 2017 Jul;31(7):1096-1110

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of this systematic review was therefore to assess the efficacy and safety of non-invasive anaesthetic methods during dermatological laser procedures.
  • The quality of evidence was rated using Grading of Recommendations Assessment, Development and Evaluation (GRADE).
  • The non-invasive anaesthetic methods (i.e. topical anaesthetic drugs, skin cooling, and pneumatic skin flattening [PSF]), types of lasers, laser settings, application time, and types of pain scales varied widely among the included studies.
  • In general, active non-invasive anaesthetic methods seemed to provide favourable results compared to placebo or no anaesthesia, and topical anaesthetic drugs and PSF seemed to result in a better pain reduction than skin cooling.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 European Academy of Dermatology and Venereology.
  • (PMID = 28107576.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


71. Gangadhar TC, Hwu WJ, Postow MA, Hamid O, Daud A, Dronca R, Joseph R, O'Day SJ, Hodi FS, Pavlick AC, Kluger H, Oxborough RP, Yang A, Gazdoiu M, Kush DA, Ebbinghaus S, Salama AKS: Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. J Immunother; 2017 Nov/Dec;40(9):334-340

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program.
  • Objective response rate was 14.5% (95% confidence interval, 12.2%-16.8%) in the treated population (n=947) and 22.1% (95% confidence interval, 18.8%-25.5%) in patients who had ≥1 response assessment reported (n=619).
  • One hundred eighty-one (19.1%) patients experienced ≥1 treatment-related AE, most commonly general disorders (8.0%), skin/subcutaneous tissue disorders (7.3%), and gastrointestinal disorders (6.4%); 29 (3.1%) patients experienced ≥1 grade 3/4 treatment-related AE.
  • The safety and efficacy observed in this expanded access program were consistent with those previously reported for similar populations and support the use of pembrolizumab for patients with advanced melanoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 29028788.001).
  • [ISSN] 1537-4513
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. El-Zawawy NA, Fareed MF, Bedaiwy MY: Synthesized zinc peroxide nanoparticles (ZnO&lt;sub&gt;2&lt;/sub&gt;-NPs): a novel antimicrobial, anti-elastase, anti-keratinase, and anti-inflammatory approach toward polymicrobial burn wounds. Int J Nanomedicine; 2017;12:6059-6073

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover, the results of in vivo histopathology assessment confirmed the potential role of ZnO<sub>2</sub>-NPs in the improvement of skin wound healing in the experimental animal models.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Microbiol Rev. 2006 Apr;19(2):403-34 [16614255.001]
  • [Cites] Med Mycol. 2004 Jun;42(3):239-46 [15283238.001]
  • [Cites] FEMS Microbiol Rev. 2007 Sep;31(5):570-91 [17645522.001]
  • [Cites] J Bacteriol. 1980 Jun;142(3):836-42 [6769912.001]
  • [Cites] Trends Microbiol. 2011 Nov;19(11):557-63 [21855346.001]
  • [Cites] Mater Sci Eng C Mater Biol Appl. 2014 Nov;44:278-84 [25280707.001]
  • [Cites] J Dent Res. 2010 Nov;89(11):1175-86 [20739694.001]
  • [Cites] Indian J Dermatol. 2011 May;56(3):259-61 [21772583.001]
  • [Cites] J Surg Res. 2012 Nov;178(1):330-8 [22835953.001]
  • [Cites] Toxicol In Vitro. 2014 Dec;28(8):1349-58 [25016134.001]
  • [Cites] Med Mycol. 2005 May;43 Suppl 1:S125-8 [16110804.001]
  • [Cites] Drug Discov Today. 2009 Feb;14(3-4):214-22 [19152839.001]
  • [Cites] J Nanobiotechnology. 2013 Dec 03;11:39 [24298944.001]
  • [Cites] Curr Infect Dis Rep. 2006 Nov;8(6):449-56 [17064638.001]
  • [Cites] Burns. 2016 Mar;42(2):428-33 [26787129.001]
  • [Cites] Burns. 1993 Aug;19(4):345-8 [8357483.001]
  • [Cites] J Pathol. 1971 May;104(1):15-29 [4398139.001]
  • [Cites] Am J Clin Pathol. 1966 Apr;45(4):493-6 [5325707.001]
  • [Cites] J Ind Microbiol Biotechnol. 2009 Feb;36(2):181-8 [19137342.001]
  • [Cites] J Burn Care Res. 2009 May-Jun;30(3):464-70 [19349889.001]
  • [Cites] Int J Pharm. 2014 Mar 25;463(2):119-26 [24361265.001]
  • [Cites] J Invest Dermatol. 2010 Jan;130(1):38-48 [19626034.001]
  • [Cites] FEMS Microbiol Lett. 2009 Oct;299(1):1-8 [19552706.001]
  • [Cites] J Clin Microbiol. 2000 May;38(5):1782-5 [10790099.001]
  • [Cites] Biochem Biophys Res Commun. 2015 Jan 30;457(1):31-6 [25529451.001]
  • [Cites] Sci Technol Adv Mater. 2008 Sep 1;9(3):035004 [27878001.001]
  • [Cites] Acta Biomater. 2013 Nov;9(11):9137-48 [23871941.001]
  • [Cites] Adv Drug Deliv Rev. 2013 Nov;65(13-14):1816-27 [23932923.001]
  • [Cites] J Trace Elem Med Biol. 2015 Apr;30:49-53 [25434301.001]
  • [Cites] Metab Eng. 2016 Nov;38:382-388 [27718358.001]
  • [Cites] Nihon Ishinkin Gakkai Zasshi. 2007;48(1):13-8 [17287718.001]
  • [Cites] Microb Pathog. 2016 Nov;100:213-220 [27671284.001]
  • [Cites] J Egypt Soc Parasitol. 2010 Apr;40(1):71-83 [20503587.001]
  • [Cites] Burns. 1989 Oct;15(5):299-302 [2511853.001]
  • [Cites] Infection. 1992 May-Jun;20(3):132-5 [1644487.001]
  • [Cites] Int J Antimicrob Agents. 2012 Aug;40(2):135-9 [22727529.001]
  • [Cites] J Immunol. 2009 Aug 1;183(3):2089-96 [19597002.001]
  • [Cites] Zhonghua Zheng Xing Shao Shang Wai Ke Za Zhi. 1989 Sep;5(3):199-200, 238-9 [2514028.001]
  • [Cites] J Clin Microbiol. 2002 May;40(5):1811-3 [11980964.001]
  • [Cites] Burns. 2002 Feb;28(1):39-46 [11834328.001]
  • [Cites] J Photochem Photobiol B. 2015 May;146:10-7 [25777265.001]
  • [Cites] Int J Nanomedicine. 2017 Feb 14;12 :1227-1249 [28243086.001]
  • [Cites] Ann Clin Microbiol Antimicrob. 2003 Oct 29;2:8 [14613587.001]
  • [Cites] Int J Antimicrob Agents. 2007 Jun;29(6):630-6 [17306965.001]
  • [Cites] Exp Parasitol. 2009 May;122(1):51-60 [19545520.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14799-804 [20668241.001]
  • [Cites] Indian J Plast Surg. 2010 Sep;43(Suppl):S37-42 [21321655.001]
  • [Cites] J Hosp Infect. 1997 Dec;37(4):317-23 [9457609.001]
  • [Cites] J Pharm Pharmacol. 1968 Mar;20(3):169-73 [4385045.001]
  • [Cites] Nanomedicine. 2014 Aug;10(6):1195-208 [24607937.001]
  • [Cites] Clin Microbiol Infect. 2005 Oct;11 Suppl 5:4-16 [16138814.001]
  • [Cites] Mycopathologia. 1991 Apr;114(1):1-8 [1713301.001]
  • [Cites] Wound Repair Regen. 2014 Jul-Aug;22(4):473-82 [24899251.001]
  • (PMID = 28860766.001).
  • [ISSN] 1178-2013
  • [Journal-full-title] International journal of nanomedicine
  • [ISO-abbreviation] Int J Nanomedicine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Keywords] NOTNLM ; anti-inflammatory / antimicrobial / burn wound infections / co-precipitation method / metal oxides nanoparticles / multidrug resistance
  •  go-up   go-down


73. Janne PA, Reckamp K, Koczywas M, Engelman JA, Camidge DR, Rajan A, Khuri F, Liang JQ, O'Connell J, Giaccone G: Efficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (E): A two-arm, phase II trial. J Clin Oncol; 2009 May 20;27(15_suppl):8063

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (E): A two-arm, phase II trial.
  • Endpoints include objective response rate, duration of response, progression-free survival, survival, safety/tolerability, and pharmacokinetics.
  • Pharmacodynamic endpoints include assessment of serum levels of HER2 and EGFR extracellular domains.
  • The most common treatment-related AEs were skin and gastrointestinal disorders, with grade 3 AEs in 19% and 13% of pts, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962636.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Jones IT, Guiha I, Goldman MP, Wu DC: A Randomized Evaluator-Blinded Trial Comparing Subsurface Monopolar Radiofrequency With Microfocused Ultrasound for Lifting and Tightening of the Neck. Dermatol Surg; 2017 Sep 08;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To compare the efficacy and safety of SMRF and MFU-V for the lifting and tightening of neck.
  • MATERIALS AND METHODS: Twenty subjects aged from 18 to 65 with moderate neck skin laxity were randomized to receive either one treatment of SMRF or MFU-V.
  • Subject assessment of firmness, texture, and laxity also significantly improved by Day 90 and persistent to Day 180.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28902019.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Capogrosso P, Ventimiglia E, Oreggia D, Salonia A, Montorsi F: Medical treatment of erectile dysfunction: too many medical prescriptions? Urologia; 2017 Aug 01;84(3):121-129

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Being user-friendly compounds with an excellent overall safety profile, PDE5is emerged as the first-line treatment for ED, thus overcoming topical alprostadil and intracavernous injections (ICIs).
  • Thereof, a careful assessment of the so-called modifiable and reversible ED risk factors along with a patient-tailored screening for potential contraindications to the treatment itself should be performed in every case.
  • Lastly, although conclusive data still lack, the potential association between life-risky PDE5is side effects (i.e. cardiovascular adverse events, melanoma skin cancer and worsening of prostate cancer outcomes) should be carefully taken into account when counselling patients for ED treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28708203.001).
  • [ISSN] 0391-5603
  • [Journal-full-title] Urologia
  • [ISO-abbreviation] Urologia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


76. Waldmann V, Narayanan K, Combes N, Jost D, Jouven X, Marijon E: Electrical cardiac injuries: current concepts and management. Eur Heart J; 2017 Apr 20;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Electrical injuries can range from minor skin burns to life threatening internal organ damage.
  • A thorough clinical assessment to ascertain the path of current through the body and possible internal injury is essential.
  • Public education and increasing workplace as well as home safety measures are key steps in prevention.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2017. For permissions, please email: journals.permissions@oup.com.
  • (PMID = 28444167.001).
  • [ISSN] 1522-9645
  • [Journal-full-title] European heart journal
  • [ISO-abbreviation] Eur. Heart J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Cardiac arrhythmias / Electric injuries / Lightning / Management / Physiopathology
  •  go-up   go-down


77. Lotz C, Schmid FF, Oechsle E, Monaghan MG, Walles H, Groeber-Becker F: Cross-linked Collagen Hydrogel Matrix Resisting Contraction To Facilitate Full-Thickness Skin Equivalents. ACS Appl Mater Interfaces; 2017 Jun 21;9(24):20417-20425

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cross-linked Collagen Hydrogel Matrix Resisting Contraction To Facilitate Full-Thickness Skin Equivalents.
  • Full-thickness skin equivalents are gathering increased interest as skin grafts for the treatment of large skin defects or chronic wounds or as nonanimal test platforms.
  • To overcome these pitfalls, we aimed to chemically cross-link the dermal layer of a full-thickness skin model composed of a collagen type I hydrogel.
  • Finally, full-thickness skin equivalents were generated by seeding human epidermal keratinocytes on the surface of the equivalents and culturing these equivalents at an air-liquid interface.
  • These results indicate that cross-linking of collagen with PEG-SG reduces contraction of collagen hydrogels and thus increases the applicability of these models as an additional tool for efficacy and safety assessment or a new generation of skin grafts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28557435.001).
  • [ISSN] 1944-8252
  • [Journal-full-title] ACS applied materials & interfaces
  • [ISO-abbreviation] ACS Appl Mater Interfaces
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; alternatives to animal testing / collagen / cross-linking / regenerative medicine / skin grafts / tissue engineering
  •  go-up   go-down


78. Narita K, Vo PTH, Yamamoto K, Kojima H, Itagaki H: Preventing false-negatives in the in vitro skin sensitization testing of acid anhydrides using interleukin-8 release assays. Toxicol In Vitro; 2017 Aug;42:69-75

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preventing false-negatives in the in vitro skin sensitization testing of acid anhydrides using interleukin-8 release assays.
  • In vitro safety tests may be used as replacements for animal tests owing to their accuracy and high-throughput performance.
  • However, several in vitro skin sensitization tests produce false-negative results such as acid anhydride.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28411127.001).
  • [ISSN] 1879-3177
  • [Journal-full-title] Toxicology in vitro : an international journal published in association with BIBRA
  • [ISO-abbreviation] Toxicol In Vitro
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Alternative / Drug exposure / False-negative / In vitro / Skin sensitization test / THP-1 cells
  •  go-up   go-down


79. Chalmers JR, Wojnarowska F, Kirtschig G, Mason J, Childs M, Whitham D, Harman K, Chapman A, Walton S, Schmidt E, Godec TR, Nunn AJ, Williams HC: A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial. Health Technol Assess; 2017 Mar;21(10):1-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial.
  • BACKGROUND: Bullous pemphigoid (BP) is an autoimmune blistering skin disorder with increased morbidity and mortality in the elderly.
  • OBJECTIVES: To evaluate the effectiveness, safety and cost-effectiveness of a strategy of initiating BP treatment with oral doxycycline or oral prednisolone.
  • We hypothesised that starting treatment with doxycycline gives acceptable short-term blister control while conferring long-term safety advantages over starting treatment with oral prednisolone.
  • FUNDING: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in <i>Health Technology Assessment</i>; Vol.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28406394.001).
  • [ISSN] 2046-4924
  • [Journal-full-title] Health technology assessment (Winchester, England)
  • [ISO-abbreviation] Health Technol Assess
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


80. Moens U, Krumbholz A, Ehlers B, Zell R, Johne R, Calvignac-Spencer S, Lauber C: Biology, evolution, and medical importance of polyomaviruses: An update. Infect Genet Evol; 2017 Oct;54:18-38

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In immunosuppressed individuals, reactivation of polyomavirus BK or JC can cause serious disease of the urogenital tract and brain, respectively, while Merkel cell polyomavirus is most probably associated with the development of a highly aggressive neuroendocrine skin tumour in elderly or patients with pre-existing conditions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier B.V. All rights reserved.
  • (PMID = 28634106.001).
  • [ISSN] 1567-7257
  • [Journal-full-title] Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases
  • [ISO-abbreviation] Infect. Genet. Evol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Disease / Evolution / Interactome / Phylogeny / Prevalence / Replication
  •  go-up   go-down


81. Luton A, Hernandez J, Patterson CR, Nielsen-Farrell J, Thompson A, Kaiser JR: Preventing Pressure Injuries in Neonates Undergoing Therapeutic Hypothermia for Hypoxic-Ischemic Encephalopathy: An Interprofessional Quality Improvement Project. Adv Neonatal Care; 2017 Aug;17(4):237-244

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interventions centered on revision of current protocols, with efforts to optimize product selection, hardwire assessment practices, and refine documentation of patient care and outcomes.
  • IMPLICATIONS FOR PRACTICE: Recognizing the unique skin protection needs of special populations within the NICU, such as those undergoing TH, is crucial.
  • IMPLICATIONS FOR RESEARCH: A paucity of literature regarding the unique skin protection needs for babies undergoing TH exists.
  • Work should be done to better describe the influence of TH on skin integrity, with the goal of identifying population-specific protective measures.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28141600.001).
  • [ISSN] 1536-0911
  • [Journal-full-title] Advances in neonatal care : official journal of the National Association of Neonatal Nurses
  • [ISO-abbreviation] Adv Neonatal Care
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Patel NU, Shukla S, Zaki J, Feldman SR: Oxymetazoline hydrochloride cream for facial erythema associated with rosacea. Expert Rev Clin Pharmacol; 2017 Oct;10(10):1049-1054

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Rosacea is a chronic skin condition characterized by transient and persistent erythema of the central face.
  • Our paper seeks to evaluate evidence for topical oxymetazoline HCl with respect to its efficacy and safety for its approved indication of treating the persistent erythema associated with rosacea.
  • Expert commentary: While assessment of available clinical trial data indicates that the medication is as effective as other available treatment for controlling rosacea-associated erythema with minimal risk of adverse effects, studies of long-term duration and direct comparison will be necessary to establish its place in treatment guidelines and clinical practice.
  • [MeSH-minor] Administration, Cutaneous. Adrenergic alpha-Agonists / administration & dosage. Adrenergic alpha-Agonists / adverse effects. Adrenergic alpha-Agonists / pharmacology. Dermatologic Agents / administration & dosage. Dermatologic Agents / adverse effects. Dermatologic Agents / pharmacology. Humans. Skin Cream. Vasoconstriction / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28837365.001).
  • [ISSN] 1751-2441
  • [Journal-full-title] Expert review of clinical pharmacology
  • [ISO-abbreviation] Expert Rev Clin Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adrenergic alpha-Agonists; 0 / Dermatologic Agents; 8VLN5B44ZY / Oxymetazoline
  • [Keywords] NOTNLM ; Erythema / FDA approval oxymetazoline hydrochloride / rhofade / rosacea / topical medication
  •  go-up   go-down


83. McKanna M, Geraci J, Hall K, Hauan B, Howell M, Huey T, Lucius A, Mendez-Eastman S, Purcell K, Raizman R, Shepherd D, Gabriel A: Clinician Panel Recommendations for Use of Negative Pressure Wound Therapy with Instillation. Ostomy Wound Manage; 2016 Apr;62(4):S1-S14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Panelists agreed NPWTi-d is primarily suited to prepare surgical or nonsurgical wounds for delayed primary closure and preparing/protecting periwound skin improves maintenance of a tight seal.
  • Panelists also emphasized the im- portance of wound assessment and documentation and recommend educating the patient, family members, and other members of the patient-care team.
  • Research to compare the safety, ef cacy, and effectiveness of NPWTi-d and other irrigation techniques on patient outcomes and research to validate these recommendations is needed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28657895.001).
  • [ISSN] 1943-2720
  • [Journal-full-title] Ostomy/wound management
  • [ISO-abbreviation] Ostomy Wound Manage
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Guo Y, Gu Z, Liu X, Liu J, Ma M, Chen B, Wang L: Rapid Analysis of Corni fructus Using Paper Spray-Mass Spectrometry. Phytochem Anal; 2017 Jul;28(4):344-350

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, a number of counterfeits of Corni fructus, such as Crataegi fructus, Lycii fructus, and grape skin are illegally sold in crude herb markets.
  • Therefore, the development of a rapid and high-throughput quality evaluation method is important for ensuring the effectiveness and safety of the crude materials of Corni fructus.
  • OBJECTIVE: To develop PS-MS chemical profiles and a semi-quantitative method of Corni fructus for quality assessment and control, and species distinction of Corni fructus.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 John Wiley & Sons, Ltd.
  • (PMID = 28239915.001).
  • [ISSN] 1099-1565
  • [Journal-full-title] Phytochemical analysis : PCA
  • [ISO-abbreviation] Phytochem Anal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Corni fructus / chemical profile / paper spray-mass spectrometry / rapid analysis / species distinction
  •  go-up   go-down


85. Oozageer Gunowa N, Hutchinson M, Brooke J, Jackson D: Pressure injuries in people with darker skin tones: A literature review. J Clin Nurs; 2017 Sep 08;
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pressure injuries in people with darker skin tones: A literature review.
  • AIMS AND OBJECTIVES: In this article, we aimed to explore the literature to ascertain what research evidence exists in relation to the identification of pressure injuries in people with dark skin tones.
  • Thus, the perceptions of people with dark skin tones and the influence of skin pigmentation on identification and management of pressure injuries is under examined.
  • Alongside the electronic data, journals, books, papers from conferences, relevant national and international organisations and reference lists were also used to help source key studies.
  • The foci of studies included the following: risk of sustaining a pressure injuries based on skin tones, identification of pressure injuries amongst people with dark skin tones, pressure injuries and place of care and socio-economic impact on pressure injuries development.
  • Overall, findings indicate that people with darker skin tones are more likely to develop higher stage pressure injuries.
  • Reasons for this are not fully elucidated; however, it may be associated with current skin assessment protocols being less effective for people who have darker skin tones resulting in early damage arising from pressure not being recognised.
  • CONCLUSION: From the literature reviewed, it can be seen that there is a lack of guidance and evidence, and people with darker skin tones are more likely in comparison with people presenting as Caucasian to develop higher stage pressure injuries.
  • RELEVANCE TO CLINICAL PRACTICE: The current literature suggests a need for researchers and clinicians to consider skin tone variances rather than ethnicity when exploring comprehensive skin assessment.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 John Wiley & Sons Ltd.
  • (PMID = 28887872.001).
  • [ISSN] 1365-2702
  • [Journal-full-title] Journal of clinical nursing
  • [ISO-abbreviation] J Clin Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Keywords] NOTNLM ; ethnicity / inequalities in health / literature review / patient safety / pressure injury / pressure ulcer
  •  go-up   go-down


86. Sharma AD, Julka PK, Rastogi A, Suri T, Rath GK, Sharma BN, Baliga VP: Assessment of efficacy, safety, and tolerability of aprepitant in adult patients with chemotherapy-induced vomiting. J Clin Oncol; 2009 May 20;27(15_suppl):e20729

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of efficacy, safety, and tolerability of aprepitant in adult patients with chemotherapy-induced vomiting.
  • The present study was undertaken to assess efficacy, safety, and tolerability of Aprepitant in adult patients with chemotherapy induced nausea and vomiting.
  • Self assessment of nausea was done by patients using a 100 mm visual analog scale.
  • Safety and tolerability was assessed through monitoring of adverse events and physical examination.
  • Overall global assessment of vomiting indicated that 19 patients (82.6 %) had very good improvement, 3 patients (13%) had good improvement and one patient (4.4%) showed fair improvement after treatment with aprepitant.
  • The most common adverse events included fever, headache, diarrhoea skin rash, constipation, and blisters.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962017.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Considine J, Hutchison AF, Rawson H, Hutchinson AM, Bucknall T, Dunning T, Botti M, Duke MM, Street M: Comparison of policies for recognising and responding to clinical deterioration across five Victorian health services. Aust Health Rev; 2017 May 25;
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most health services' definitions of physiological observations fulfilled national standards in terms of minimum parameters and frequency of assessment.
  • </b> Recognising and responding to clinical deterioration is a major patient safety priority.
  • Although nurses are largely responsible for physiological observations and escalation of care, they have little authority to direct frequency of observations and triggers for care escalation or tailor assessment to individual patient needs.
  • </b> Inconsistencies in recommendations regarding physiological observations and escalation of care criteria may create patient safety issues when students and staff work across organisations or move from one organisation to another.
  • The validity of other parameters, such as appearance, pain, skin colour and cognition, warrant further consideration as early indicators of deterioration that may be used by nurses to identify clinical deterioration earlier.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28538140.001).
  • [ISSN] 0156-5788
  • [Journal-full-title] Australian health review : a publication of the Australian Hospital Association
  • [ISO-abbreviation] Aust Health Rev
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


88. Dornic N, Ficheux AS, Roudot AC: Consumption of cosmetic products by the French population. Third part: Product exposure amount. Food Chem Toxicol; 2017 Aug;106(Pt A):209-222

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of the present study was to generate Product Exposure Amount data, i.e. the amounts of cosmetics applied to the skin among the French population using the raw data collected during the previous enquiry.
  • These data are useful to derive Consumer exposure level data which are paramount for skin sensitization risk assessments.
  • The results showed that some data used by the International Fragrance Association in skin sensitization risk assessments, in particular facial care products and deodorants, could be unsuitable for the protection of French consumers.
  • These data will be useful for the implementation of the Quantitative Risk Assessment for skin sensitization among the French population.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Consumer Product Safety / standards. Databases, Factual. Female. France. Humans. Infant. Male. Skin. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28571772.001).
  • [ISSN] 1873-6351
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cosmetics
  • [Keywords] NOTNLM ; Adults / Babies / Children / Cosmetic products / Product Exposure Amount / Skin sensitization
  •  go-up   go-down


89. Myhill T, Coulson W, Nixon P, Royal S, McCormack T, Kerrouche N: Use of Supplementary Patient Education Material Increases Treatment Adherence and Satisfaction Among Acne Patients Receiving Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel in Primary Care Clinics: A Multicenter, Randomized, Controlled Clinical Study. Dermatol Ther (Heidelb); 2017 Oct 12;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Other assessments included a subject appreciation questionnaire, a physician questionnaire, and safety.
  • According to the subject appreciation questionnaire, the SEM was more helpful to adhere to treatment (56.7%) versus more visits (32.3%) and A/BPO alone (15.2%), better use the product (70%, 61.3%, and 54.5%, respectively), and better manage skin irritation (53.3%, 48.4%, and 36.4%, respectively).
  • Safety assessment showed fewer treatment-related adverse events in the A/BPO + SEM group.
  • FUNDING: Nestle Skin Health-Galderma R&D.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 29027127.001).
  • [ISSN] 2193-8210
  • [Journal-full-title] Dermatology and therapy
  • [ISO-abbreviation] Dermatol Ther (Heidelb)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; Acne / Adapalene 0.1%/benzoyl peroxide 2.5% gel / Patient adherence / Primary care / Supplementary patient education
  •  go-up   go-down


90. Rodriguez-Granillo GA: Delayed enhancement cardiac computed tomography for the assessment of myocardial infarction: from bench to bedside. Cardiovasc Diagn Ther; 2017 Apr;7(2):159-170

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delayed enhancement cardiac computed tomography for the assessment of myocardial infarction: from bench to bedside.
  • We review the available evidence of DE imaging for the assessment of myocardial infarction (MI) using cardiac CT (CTDE), from animal to clinical studies, and from 16-slice CT to dual-energy CT systems (DECT).
  • Although both CMR and gadolinium agents have been originally deemed innocuous, a number of concerns (though inconclusive and very rare) have been recently issued regarding safety issues, including DNA double-strand breaks related to CMR, and gadolinium-associated nephrogenic systemic fibrosis and deposition in the skin and certain brain structures.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Circ Cardiovasc Imaging. 2011 Nov;4(6):610-9 [21911738.001]
  • [Cites] Circ Cardiovasc Imaging. 2015 Sep;8(9):e003697 [26338876.001]
  • [Cites] Circulation. 2014 Aug 5;130(6):484-95 [25092278.001]
  • [Cites] J Am Coll Cardiol. 2012 Feb 21;59(8):730-8 [22340265.001]
  • [Cites] Eur Radiol. 2011 Oct;21(10):2091-9 [21573970.001]
  • [Cites] J Cardiovasc Comput Tomogr. 2015 Jul-Aug;9(4):321-8 [26088379.001]
  • [Cites] Circulation. 1999 Nov 9;100(19):1992-2002 [10556226.001]
  • [Cites] J Magn Reson Imaging. 2007 Aug;26(2):401-4 [17610281.001]
  • [Cites] Eur J Radiol. 2015 Oct;84(10 ):1915-20 [26152868.001]
  • [Cites] N Engl J Med. 1983 Aug 11;309(6):331-6 [6866068.001]
  • [Cites] Circulation. 2006 Jan 24;113(3):394-404 [16432071.001]
  • [Cites] Invest Radiol. 2008 Nov;43(11):773-81 [18923256.001]
  • [Cites] Radiology. 2016 Jul;280(1):49-57 [27322972.001]
  • [Cites] Circ Cardiovasc Imaging. 2016 Oct;9(10 ): [27894070.001]
  • [Cites] J Am Coll Cardiol. 2006 Jul 4;48(1):144-52 [16814660.001]
  • [Cites] Cardiovasc Diagn Ther. 2014 Oct;4(5):350-6 [25414821.001]
  • [Cites] JACC Cardiovasc Imaging. 2013 Oct;6(10 ):1062-71 [24011773.001]
  • [Cites] JACC Cardiovasc Imaging. 2016 Dec;9(12 ):1392-1402 [27450876.001]
  • [Cites] Eur Heart J Cardiovasc Imaging. 2014 Feb;15(2):216-25 [24243144.001]
  • [Cites] Invest Radiol. 2011 Jul;46(7):450-6 [21427592.001]
  • [Cites] J Cardiovasc Comput Tomogr. 2009 Nov-Dec;3(6):409-11 [20083062.001]
  • [Cites] Radiology. 2014 Mar;270(3):708-16 [24475833.001]
  • [Cites] JACC Cardiovasc Imaging. 2009 Sep;2(9):1072-81 [19761985.001]
  • [Cites] Neuroradiology. 2016 May;58(5):433-41 [26873830.001]
  • [Cites] Int J Cardiovasc Imaging. 2014 Aug;30(6):1145-50 [24810781.001]
  • [Cites] Invest Radiol. 2016 May;51(5):280-9 [26953564.001]
  • [Cites] Clin Imaging. 2015 Sep-Oct;39(5):809-14 [25935519.001]
  • [Cites] J Am Coll Cardiol. 2005 Jun 21;45(12 ):2042-7 [15963407.001]
  • [Cites] Expert Rev Pharmacoecon Outcomes Res. 2015;15(4):625-33 [26027879.001]
  • [Cites] J Am Coll Cardiol. 2009 Sep 15;54(12):1072-84 [19744616.001]
  • [Cites] Int J Cardiovasc Imaging. 2011 Jun;27(5):647-56 [21547377.001]
  • [Cites] J Cardiovasc Magn Reson. 2010 Oct 07;12:56 [20929540.001]
  • [Cites] Neuropsychiatr Dis Treat. 2008 Apr;4(2):487-93 [18728736.001]
  • [Cites] J Cardiovasc Magn Reson. 2016 Jul 18;18(1):45 [27430331.001]
  • [Cites] J Am Coll Cardiol. 2004 Jun 16;43(12 ):2260-4 [15193690.001]
  • [Cites] J Cardiovasc Magn Reson. 2016 Jan 11;18:3 [26754743.001]
  • [Cites] Radiol Med. 2010 Oct;115(7):1003-14 [20221710.001]
  • [Cites] Eur J Radiol. 2015 Apr;84(4):637-42 [25600679.001]
  • [Cites] Circ Cardiovasc Imaging. 2012 May 1;5(3):333-40 [22447807.001]
  • [Cites] Invest Radiol. 2013 Dec;48(12 ):851-6 [23907104.001]
  • [Cites] J Am Coll Cardiol. 2009 May 5;53(18):1699-707 [19406346.001]
  • [Cites] Eur Radiol. 2007 Feb;17 (2):475-83 [16802125.001]
  • [Cites] J Cardiovasc Magn Reson. 2014 Oct 03;16:83 [25279683.001]
  • [Cites] Eur J Radiol. 2011 Nov;80(2):326-30 [20138452.001]
  • [Cites] Radiology. 2010 Mar;254(3):718-28 [20177087.001]
  • [Cites] Invest Radiol. 2013 Jan;48(1):41-5 [23192166.001]
  • [Cites] Circulation. 2007 Apr 17;115(15):2006-14 [17389270.001]
  • [Cites] Eur Heart J. 2013 Aug;34(30):2340-5 [23793096.001]
  • [Cites] Int J Cardiovasc Imaging. 2017 Apr;33(4):577-584 [27873128.001]
  • [Cites] Eur Heart J. 2016 Feb 21;37(8):684-92 [26385959.001]
  • [Cites] Int J Cardiovasc Imaging. 2014 Mar;30(3):659-67 [24449335.001]
  • [Cites] Int J Cardiovasc Imaging. 2014 Dec;30(8):1613-20 [25053514.001]
  • [Cites] PLoS One. 2015 Mar 27;10(3):e0121326 [25816056.001]
  • [Cites] J Cardiovasc Comput Tomogr. 2014 Jul-Aug;8(4):289-98 [25151921.001]
  • [Cites] J Cardiovasc Comput Tomogr. 2013 May-Jun;7(3):173-81 [23849490.001]
  • [Cites] Circulation. 2006 Feb 14;113(6):823-33 [16461822.001]
  • [Cites] Radiology. 1999 Oct;213(1):247-57 [10540668.001]
  • [Cites] Ann Intern Med. 2015 Apr 7;162(7):474-84 [25844996.001]
  • [Cites] AJR Am J Roentgenol. 2014 Jul;203(1):W70-7 [24951230.001]
  • [Cites] JACC Cardiovasc Imaging. 2016 Jul;9(7):822-32 [26897692.001]
  • [Cites] Eur Radiol. 2015 Aug;25(8):2291-7 [25693664.001]
  • [Cites] Circ Cardiovasc Imaging. 2014 Mar;7(2):250-8 [24363358.001]
  • [Cites] J Am Coll Cardiol. 2010 Jun 1;55(22):2459-69 [20510213.001]
  • [Cites] Cardiovasc Diagn Ther. 2015 Feb;5(1):79-85 [25774354.001]
  • [Cites] JACC Cardiovasc Imaging. 2009 Apr;2(4):412-20 [19580722.001]
  • [Cites] Eur Radiol. 2013 Apr;23(4):1034-43 [23064716.001]
  • [Cites] Yonsei Med J. 2010 Sep;51(5):683-91 [20635442.001]
  • [Cites] JACC Cardiovasc Imaging. 2014 Sep;7(9):940-52 [25212800.001]
  • [Cites] Clin J Am Soc Nephrol. 2010 Mar;5(3):484-9 [20093350.001]
  • [Cites] Invest Radiol. 2010 Jun;45(6):306-13 [20421800.001]
  • [Cites] J Cardiovasc Comput Tomogr. 2015 Jul-Aug;9(4):313-20 [25977115.001]
  • (PMID = 28540211.001).
  • [ISSN] 2223-3652
  • [Journal-full-title] Cardiovascular diagnosis and therapy
  • [ISO-abbreviation] Cardiovasc Diagn Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China (Republic : 1949- )
  • [Keywords] NOTNLM ; Cardiac imaging / dual energy / late enhancement / magnetic resonance / necrosis
  •  go-up   go-down


91. Thomas KS, Bradshaw LE, Sach TH, Cowdell F, Batchelor JM, Lawton S, Harrison EF, Haines RH, Ahmed A, Dean T, Burrows NP, Pollock I, Buckley HK, Williams HC, Llewellyn J, Crang C, Grundy JD, Guiness J, Gribbin A, Wake EV, Mitchell EJ, Brown SJ, Montgomery AA: Randomised controlled trial of silk therapeutic garments for the management of atopic eczema in children: the CLOTHES trial. Health Technol Assess; 2017 Apr;21(16):1-260

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Atopic eczema (AE) is a chronic, itchy, inflammatory skin condition that affects the quality of life of children and their families.
  • Secondary outcomes - patient-reported eczema symptoms (Patient Oriented Eczema Measure); global assessment of severity (Investigator Global Assessment); quality of life of the child (Atopic Dermatitis Quality of Life, Child Health Utility - 9 Dimensions), family (Dermatitis Family Impact Questionnaire) and main carer (EuroQoL-5 Dimensions-3 Levels); use of standard eczema treatments (e.g. emollients, topical corticosteroids); and cost-effectiveness.
  • Safety outcomes - number of skin infections and hospitalisations for AE.
  • Skin infections occurred in 39 out of 141 (28%) and 36 out of 142 (25%) participants for standard care and silk clothing groups, respectively.
  • FUNDING: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in <i>Health Technology Assessment</i>; Vol.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28409557.001).
  • [ISSN] 2046-4924
  • [Journal-full-title] Health technology assessment (Winchester, England)
  • [ISO-abbreviation] Health Technol Assess
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


92. Riccò M, Razio B, Poletti L, Panato C: Knowledge, attitudes, and sun-safety practices among agricultural workers in the Autonomous Province of Trento, North-Eastern Italy (2016). G Ital Dermatol Venereol; 2017 Sep 08;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Knowledge, attitudes, and sun-safety practices among agricultural workers in the Autonomous Province of Trento, North-Eastern Italy (2016).
  • BACKGROUND: The purpose of this study was to determine evaluate sun safety knowledge, attitudes and practices (KAP) among agricultural workers (AWs) in the Autonomous Province of Trento (North-Eastern Italy).
  • Sun protective behaviours were irregularly referred by participants, in particular receiving medical skin assessment by a dermatologist (33.8%), avoiding sun radiations at noon and taking rest breaks in shady areas (30.9%), and wearing sunscreen (13.3%).
  • CONCLUSIONS: Our findings indicate that AWs are not appropriately aware of the risks associated with occupational exposure to solar radiation, and eventually report inadequate skin cancer prevention practices.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28895375.001).
  • [ISSN] 1827-1820
  • [Journal-full-title] Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia
  • [ISO-abbreviation] G Ital Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


93. Fahs I, Shrayteh Z, Abdulkhalek R, Salameh P, Hallit S, Malaeb D: Professional practice evaluation of emergency department prescriptions for community-acquired infections in Lebanon. Int J Infect Dis; 2017 Sep 21;64:74-79

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The assessment of antibiotic therapy based on adherence to international guidelines, including the choice of antibiotic, dosing, or both, was considered for analysis.
  • Adherence to international guidelines was noted in only 32.6% of cases; the frequency was highest for skin and soft tissue infections (50.0%), followed by urinary tract infections (40%).
  • This emphasizes the importance of monitoring the use of antibiotics in the ED, as there is growing concern for antibiotic resistance and healthcare safety.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.
  • (PMID = 28941632.001).
  • [ISSN] 1878-3511
  • [Journal-full-title] International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • [ISO-abbreviation] Int. J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Adherence / Antibiotic / Emergency department / Guidelines / Infectious diseases
  •  go-up   go-down


94. Al Jarallah M, Kassir R, El-Barbari M, Ali S, Debs T, Chouillard E: Three-Year Follow-Up of Laparoscopic Reduced Port Sleeve Gastrectomy in 808 Consecutive Patients. Obes Surg; 2017 May 04;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Preliminary and safety profile of <sub>R</sub>LSG as well as 3 years weight loss outcome are hereby discussed.
  • The <sub>R</sub>LSG procedure was performed using only two skin incisions.
  • Moreover, 3-year follow-up assessment confirmed adequate % EWL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obes Surg. 2014 Jul;24(7):1102-8 [24817374.001]
  • [Cites] Obes Surg. 2014 Sep;24(9):1552-62 [24965545.001]
  • [Cites] Obes Surg. 2011 Nov;21(11):1664-70 [21789509.001]
  • [Cites] Surg Endosc. 2015 Jun;29(6):1439-44 [25159654.001]
  • [Cites] Obes Surg. 2015 Aug;25(8):1502-10 [25986425.001]
  • [Cites] Am J Surg. 2008 Nov;196(5):e56-9 [18954593.001]
  • [Cites] Obes Surg. 2006 Sep;16(9):1138-44 [16989696.001]
  • [Cites] Obes Surg. 2015 Jan;25(1):143-58 [25355456.001]
  • [Cites] Diabetologia. 2013 Sep;56(9):1914-8 [23765186.001]
  • [Cites] Obes Surg. 2014 Oct;24(10):1617-24 [24827405.001]
  • [Cites] Obes Surg. 2010 Oct;20(10):1448-55 [20383753.001]
  • [Cites] Asian J Endosc Surg. 2015 Feb;8(1):1-10 [25496345.001]
  • [Cites] Obes Surg. 2013 May;23(5):613-21 [23207829.001]
  • [Cites] World J Gastroenterol. 2015 Nov 7;21(41):11804-14 [26557004.001]
  • [Cites] Surg Endosc. 2012 Sep;26(9):2521-6 [22476829.001]
  • [Cites] Obes Surg. 2007 Nov;17(11):1435-41 [18219769.001]
  • [Cites] Surg Endosc. 2006 Jun;20(6):859-63 [16738970.001]
  • [Cites] Obesity (Silver Spring). 2014 Sep;22(9):2026-31 [24891156.001]
  • [Cites] Obes Surg. 2010 May;20(5):535-40 [20094819.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2009 Dec;19(6):755-8 discussion 759 [19747034.001]
  • [Cites] Surg Obes Relat Dis. 2011 Sep-Oct;7(5):581-6 [21126921.001]
  • [Cites] Int J Surg. 2015 Oct;22:67-71 [26278664.001]
  • [Cites] Surg Obes Relat Dis. 2015 Nov-Dec;11(6):1383-5 [26278194.001]
  • (PMID = 28474321.001).
  • [ISSN] 1708-0428
  • [Journal-full-title] Obesity surgery
  • [ISO-abbreviation] Obes Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Gastrectomy / Laparoscopy / Obesity / Sleeve / Surgery
  •  go-up   go-down


95. Jung YS, Lee JH, Bae JM, Lee DW, Kim GM: Assessment of the efficacy and safety of a new complex skin cream in Asian women: A controlled clinical trial. J Cosmet Dermatol; 2017 May 16;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of the efficacy and safety of a new complex skin cream in Asian women: A controlled clinical trial.
  • BACKGROUND: Medical products such as hydroquinone and tretinoin have been widely used to treat various types of skin hyperpigmentation.
  • AIMS: To evaluate the efficacy and safety of a new brightening complex cream containing niacinamide, tranexamic acid, oxyresveratrol, glutathione disulfide, and linoleic acid.
  • PATIENTS AND METHODS: A total of 26 Korean women seeking to lighten their skin were enrolled.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 Wiley Periodicals, Inc.
  • (PMID = 28512843.001).
  • [ISSN] 1473-2165
  • [Journal-full-title] Journal of cosmetic dermatology
  • [ISO-abbreviation] J Cosmet Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Asian / skin brightening / topical cream
  •  go-up   go-down


96. Wohlrab J, Gilbrich F, Wolff L, Fischer M, Philipp S: [Preclinical safety evaluation of chloral hydrate after topical application using the example of psoriatic itch]. Hautarzt; 2017 Mar;68(3):217-223
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preclinical safety evaluation of chloral hydrate after topical application using the example of psoriatic itch].
  • OBJECTIVES: For lack of clinical safety data, preclinical tests for cutaneous cytotoxicity and calculations for systemic bioavailability after topical application have been performed.
  • CONCLUSION: The present data cannot fully remove safety concerns for topical application of chloral hydrate in the formulation favoured by the NRF (Neues Rezepturformularium)-the so-called 1‑2-3-cream.
  • For a better assessment of harmlessness, tests for cutaneous bioavailability (concentration-time profile) on human skin and clinical studies would be necessary.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Pediatr. 2005 Jul;164(7):403-7 [15798911.001]
  • [Cites] Mediators Inflamm. 2007;2007:64727 [18288273.001]
  • [Cites] J Formos Med Assoc. 2006 Mar;105(3):235-7 [16520840.001]
  • [Cites] J Appl Toxicol. 2012 Jun;32(6):387-94 [21365670.001]
  • [Cites] Toxicol Appl Pharmacol. 2003 Dec 1;193(2):281-92 [14644628.001]
  • [Cites] Cancer Lett. 2002 Nov 8;185(1):13-9 [12142074.001]
  • [Cites] Toxicol In Vitro. 1993 Jul;7(4):505-10 [20732242.001]
  • [Cites] Methods Mol Biol. 2013;989:275-83 [23483402.001]
  • [Cites] J Immunol Methods. 1984 Mar 30;68(1-2):167-75 [6707477.001]
  • [Cites] J Expo Sci Environ Epidemiol. 2012 Jul;22(4):393-7 [22549718.001]
  • [Cites] Harefuah. 1996 Jan 1;130(1):14-5, 71 [8682371.001]
  • [Cites] J Toxicol Environ Health A. 1998 Jun 12;54(3):209-26 [9643873.001]
  • [Cites] Med J Aust. 1988 Dec 5-19;149(11-12):686-8 [3059159.001]
  • [Cites] Burns. 1996 Feb;22(1):35-9 [8719314.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1995 Jun;31(6):447-55 [8589888.001]
  • [Cites] Neuroscience. 1999;93(2):713-22 [10465455.001]
  • [Cites] Prescrire Int. 1998 Jun;7(35):88-9 [10342927.001]
  • [Cites] Am J Clin Dermatol. 2016 Jun;17 (3):257-63 [26935938.001]
  • [Cites] Pediatrics. 1993 Sep;92(3):471-3 [8361811.001]
  • [Cites] Am J Med Sci. 1961 Nov;242:574-8 [13880824.001]
  • [Cites] Radiat Res. 1976 Nov;68(2):258-74 [981524.001]
  • [Cites] Cell Mol Life Sci. 2004 Nov;61(21):2774-81 [15549181.001]
  • [Cites] Eur J Pain. 2016 Jan;20(1):41-6 [26415584.001]
  • [Cites] Dermatology. 2013;227(2):134-45 [24051528.001]
  • [Cites] Yonsei Med J. 1996 Jun;37(3):186-93 [8826784.001]
  • [Cites] J Rheumatol. 2008 Jul;35(7):1438-42 [18609741.001]
  • [Cites] Adv Exp Med Biol. 1980;132:533-41 [6999874.001]
  • [Cites] Methods Mol Biol. 2011;769:25-30 [21748666.001]
  • [Cites] Pediatr Emerg Care. 1999 Dec;15(6):432-5 [10608336.001]
  • [Cites] AJR Am J Roentgenol. 1997 Oct;169(4):1195 [9308493.001]
  • [Cites] Nat Protoc. 2007;2(2):329-33 [17406593.001]
  • [Cites] Pediatr Blood Cancer. 2013 Mar;60(3):518-20 [23151940.001]
  • [Cites] Am J Psychiatry. 2000 Oct;157(10):1706 [11007738.001]
  • [Cites] Br Med J. 1870 Apr 2;1(483):330 [20745816.001]
  • [Cites] Br J Dermatol. 2000 Nov;143(5):969-73 [11069504.001]
  • [Cites] Toxicol Pathol. 2000 Jul-Aug;28(4):610-8 [10930049.001]
  • [Cites] J Anal Toxicol. 1980 Mar-Apr;4(2):99-101 [7421142.001]
  • [Cites] Int J Biol Macromol. 2015 May;76:236-41 [25748846.001]
  • [Cites] Dev Pharmacol Ther. 1991;17(1-2):116-20 [1811917.001]
  • [Cites] Arch Dermatol Res. 2010 Sep;302(7):507-15 [20455067.001]
  • [Cites] Toxicol Lett. 1990 Jul;52(2):129-33 [2377996.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1661-9 [24372845.001]
  • [Cites] Natl Toxicol Program Tech Rep Ser. 2002 Dec;(503):1-218 [12533745.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1995;63:245-69 [9097095.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Jul 22;261(1):100-7 [10405330.001]
  • [Cites] Lab Invest. 1994 Nov;71(5):745-54 [7967526.001]
  • [Cites] Hautarzt. 2016 Aug;67(8):601-5 [27376751.001]
  • (PMID = 27981385.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; Administration / Antipruritics / Bioavailability / Cytotoxicity / Psoriasis
  •  go-up   go-down


97. Vukmanović S, Sadrieh N: Skin sensitizers in cosmetics and beyond: potential multiple mechanisms of action and importance of T-cell assays for in vitro screening. Crit Rev Toxicol; 2017 May;47(5):415-432

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin sensitizers in cosmetics and beyond: potential multiple mechanisms of action and importance of T-cell assays for in vitro screening.
  • The combination of the proposed tests, along with the existing assays, should further enhance animal-free assessment of sensitizing potential of individual chemicals.
  • [MeSH-minor] Computer Simulation. Consumer Product Safety. Dermatitis, Allergic Contact. Humans. In Vitro Techniques. Skin. T-Lymphocytes

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28326907.001).
  • [ISSN] 1547-6898
  • [Journal-full-title] Critical reviews in toxicology
  • [ISO-abbreviation] Crit. Rev. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Allergens; 0 / Cosmetics
  • [Keywords] NOTNLM ; Allergic contact dermatitis / HLA / T cells / cosmetics / delayed-type hypersensitivity / dendritic cells / fragrance / hapten / human-repeated insult patch test / keratinocytes / local lymph node assay / skin sensitization
  •  go-up   go-down


98. Watzek N, Berger F, Kolle SN, Kaufmann T, Becker M, van Ravenzwaay B: Assessment of skin sensitization under REACH: A case report on vehicle choice in the LLNA and its crucial role preventing false positive results. Regul Toxicol Pharmacol; 2017 Apr;85:25-32
Hazardous Substances Data Bank. ACETONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of skin sensitization under REACH: A case report on vehicle choice in the LLNA and its crucial role preventing false positive results.
  • In the EU, chemicals with a production or import volume in quantities of one metric ton per year or more have to be tested for skin sensitizing properties under the REACH regulation.
  • This manuscript describes a case study highlighting the importance of understanding the chemistry of the test material during testing for 'skin sensitization' of MCDA (mixture of 2,4- and 2,6-diamino-methylcyclohexane) with particular focus on the vehicle used.
  • Finally, a classification of MCDA as skin sensitizer according to the Globally Harmonized System (GHS) was not justified.

  • Hazardous Substances Data Bank. Propylene glycol .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Inc. All rights reserved.
  • (PMID = 28159477.001).
  • [ISSN] 1096-0295
  • [Journal-full-title] Regulatory toxicology and pharmacology : RTP
  • [ISO-abbreviation] Regul. Toxicol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Allergens; 0 / Cyclohexylamines; 0 / Excipients; 0 / Haptens; 0 / Olive Oil; 1364PS73AF / Acetone; 6DC9Q167V3 / Propylene Glycol
  • [Keywords] NOTNLM ; AOO / Adverse Outcome Pathway / BrdU-ELISA / False positive results / Local Lymph Node Assay / Skin sensitization / Test substance stability in the vehicle
  •  go-up   go-down


99. Lawrence C, Harnish DA, Sandoval-Powers M, Mills D, Bergman M, Heimbuch BK: Assessment of half-mask elastomeric respirator and powered air-purifying respirator reprocessing for an influenza pandemic. Am J Infect Control; 2017 Aug 22;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of half-mask elastomeric respirator and powered air-purifying respirator reprocessing for an influenza pandemic.
  • METHODS: Five half-mask elastomeric respirator models and 3 powered air-purifying respirator models were contaminated with influenza virus and artificial skin oil on multiple surfaces.
  • CONCLUSIONS: The methods defined as part of this study are effective for eliminating viable influenza in the presence of artificial skin oil on most of the RPD surfaces tested.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Association for Professionals in Infection Control and Epidemiology, Inc. All rights reserved.
  • (PMID = 28844381.001).
  • [ISSN] 1527-3296
  • [Journal-full-title] American journal of infection control
  • [ISO-abbreviation] Am J Infect Control
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cleaning infection control / Disinfection / Mucin / N95 / Respiratory protection / Reuse / Sebum
  •  go-up   go-down


100. Thanasarnaksorn W, Siramangkhalanon V, Duncan DI, Belenky I: Fractional ablative and nonablative radiofrequency for skin resurfacing and rejuvenation of Thai patients. J Cosmet Dermatol; 2017 Aug 31;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fractional ablative and nonablative radiofrequency for skin resurfacing and rejuvenation of Thai patients.
  • BACKGROUND: Fractional radiofrequency (RF) technology is often the preferable skin resurfacing treatment, especially among Asian patients.
  • AIMS: The aim of this study was to evaluate the efficacy and safety of a fractional RF handpiece such as this, on the Thai population.
  • The clinical assessment included a pain score, satisfaction survey, physician assessment, a combined patient and physician's assessment of skin condition, and clinical photographic assessments.
  • Positive correlation was found between patient satisfaction and the physician's assessment.
  • The skin condition assessment showed an increase from an average of 4.2 to 7.9.
  • CONCLUSIONS: This study clinically and histologically supports the efficacy of fractional RF handpiece in question with a high safety profile.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 Wiley Periodicals, Inc.
  • (PMID = 28857466.001).
  • [ISSN] 1473-2165
  • [Journal-full-title] Journal of cosmetic dermatology
  • [ISO-abbreviation] J Cosmet Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Asian patients / histological evaluation / radiofrequency / scar / skin resurfacing
  •  go-up   go-down






Advertisement